Document:

2004 Equity Incentive Plan of Therapeutics

 Exhibit 4.1 
  
 2004 EQUITY INCENTIVE PLAN 
 OF 
 DUSKA THERAPEUTICS, INC. 
 (as amended) 
  

	1.	PURPOSES OF THE PLAN 

  
 The purposes of the 2004 Equity Incentive Plan (“Plan”) of DUSKA THERAPEUTICS, INC., a Nevada corporation (the “Company”), are to:

  
 1.1 Encourage selected employees, directors, consultants and
advisers to improve operations and increase the profitability of the Company; 
  
 1.2 Encourage selected employees, directors, consultants and advisers to accept or continue employment or association with the Company or its Affiliates; and 
  
 1.3 Increase the interest of selected employees, directors, consultants and
advisers in the Company’s welfare through participation in the growth in value of the common stock of the Company, par value $.001 per share (the “Common Stock”). 
  

	2.	TYPES OF AWARDS; ELIGIBLE PERSONS 

  
 2.1 The Administrator (as defined below) may, from time to time, take the following action, separately or in combination, under the Plan: (i) grant
“incentive stock options” (“ISOs”) intended to satisfy the requirements of Section 422 of the Internal Revenue Code of 1986, as amended, and the regulations thereunder (the “Code”); (ii) grant “non-qualified
options” (“NQOs,” and together with ISOs, “Options”); (iii) grant or sell Common Stock subject to restrictions (“restricted stock”) and (iv) grant stock appreciation rights (in general, the right to receive the
excess of the fair market value of Common Stock on the exercise date over its fair market value on the grant date (“SARs”)), either in tandem with Options or as separate and independent grants. Any such awards may be made to employees,
including employees who are officers or directors, and to individuals described in Section 1 of this Plan who the Administrator believes have made or will make a contribution to the Company or any Affiliate (as defined below); provided,
however, that only a person who is an employee of the Company or any Affiliate at the date of the grant of an Option is eligible to receive ISOs under the plan. The term “Affiliate” as used in this Plan means a parent or subsidiary
corporation as defined in the applicable provisions (currently Sections 424(e) and (f), respectively) of the Code. The term “employee” includes an officer or director who is an employee of the Company. The term “consultant”
includes persons employed by, or otherwise affiliated with, a consultant. The term “adviser” includes persons employed by, or otherwise affiliated with, an adviser. 
  
 2.2 Except as otherwise expressly set forth in this Plan, no right or benefit under this Plan shall be subject in any manner
to anticipation, alienation, hypothecation, or charge, and any such attempted action shall be void. No right or benefit under this Plan shall in any manner be liable for or subject to debts, contracts, liabilities, or torts of any option holder or
any other person except as otherwise may be expressly required by applicable law. 
  

	3.	STOCK SUBJECT TO THIS PLAN; MAXIMUM NUMBER OF GRANTS 

  
 Subject to the provisions of Sections 6.1.1 and 8.2 of this Plan, the total number of shares of Common Stock which may be offered, or issued as restricted
stock or on the exercise of Options or SARs under the Plan shall not exceed six million (6,000,000) shares of Common Stock. The shares subject to an Option or SAR granted under the Plan which expire, terminate or are cancelled unexercised shall
become available again for grants under this Plan. If shares of restricted stock awarded under the Plan are forfeited to the Company or repurchased by the Company, the number of shares forfeited or repurchased shall again be available under the
Plan. Where the exercise price of an Option is paid by means of the optionee’s surrender of previously owned shares of Common Stock or the Company’s withholding of shares otherwise issuable upon exercise of the Option as may be permitted
herein, only the net number of shares issued and which remain outstanding in connection with such exercise shall be deemed “issued” and no longer available for issuance under this Plan. No eligible person shall be granted Options or other
awards during any twelve-month period covering more than four hundred thousand (400,000) shares. 
  

	4.	ADMINISTRATION 

  
 4.1 This Plan shall be administered by the Board of Directors of the Company (the “Board”) or by a committee (the “Committee”) to
which administration of this Plan, or of part of this Plan, is delegated by the Board (in either case, the “Administrator”). The Board shall appoint and remove members of the Committee in its discretion in accordance with applicable laws.
At the Board’s discretion, the Committee may be comprised solely of “non-employee directors” within the meaning of Rule 16b-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or “outside
directors” within the meaning of Section 162(m) of the Code. The Administrator may delegate non-discretionary administrative duties to such employees of the Company as the Administrator deems proper and the Board, in its absolute discretion,
may at any time and from time to time exercise any and all rights and duties of the Administrator under this Plan. 
  
 4.2 Subject to the other provisions of this Plan, the Administrator shall have the authority, in its discretion: (i) to grant Options and SARs and grant
or sell restricted stock; (ii) to determine the fair market value of the Common Stock subject to Options or other awards; (iii) to determine the exercise price of Options granted, the economic terms of SARs granted, or the offering price of
restricted stock; (iv) to determine the persons to whom, and the time or times at which, Options or SARs shall be granted or restricted stock granted or sold, and the number of shares subject to each Option or SAR or the number of shares of
restricted stock granted or sold; (v) to construe and interpret the terms and provisions of this Plan, of any applicable agreement and all Options and SARs granted under this Plan, and of any restricted stock award under this Plan; (vi) to
prescribe, amend, and rescind rules and regulations relating to this Plan; (vii) to determine the terms and provisions of each Option and SAR granted and award of restricted stock (which need not be identical), including but not limited to, the time
or times at which Options and SARs shall be exercisable or the time at which the restrictions on restricted stock shall lapse; (viii) with the consent of the grantee, to rescind any award or exercise of an Option or SAR and to modify or amend the
terms of any Option, SAR or restricted stock; (ix) to reduce the exercise price of any Option, the base value from which appreciation is to be determined with 

  

 2 

 
respect to an SAR or the purchase price of restricted stock; (x) to accelerate or defer (with the consent of the grantee) the exercise date of any Option or
SAR or the date on which the restrictions on restricted stock lapse; (xi) to issue shares of restricted stock to an optionee in connection with the accelerated exercise of an Option by such optionee; (xii) to authorize any person to execute on
behalf of the Company any instrument evidencing the grant of an Option. SAR or award of restricted stock; (xiii) to determine the duration and purposes of leaves of absence which may be granted to participants without constituting a termination of
their employment for the purposes of the Plan; and (xiv) to make all other determinations deemed necessary or advisable for the administration of this Plan, any applicable agreement, Option, SAR or award of restricted stock. 
  
 4.3 All questions of interpretation, implementation, and application of this
Plan or any agreement or Option, SAR or award of restricted stock shall be determined by the Administrator, which determination shall be final and binding on all persons. 
  

	5.	GRANTING OF OPTIONS AND SARS; AGREEMENTS 

  
 5.1 No Options or SARs shall be granted under this Plan after ten (10) years from the date of adoption of this Plan by the Board. 
  
 5.2 Each Option and SAR shall be evidenced by a written agreement, in form
satisfactory to the Administrator, executed by the Company and the person to whom such grant is made. In the event of a conflict between the terms or conditions of an agreement and the terms and conditions of this Plan, the terms and conditions of
this Plan shall govern. 
  
 5.3 Each agreement shall specify
whether the Option it evidences is an NQO or an ISO, provided, however, all Options granted under this Plan to non-employee directors, consultants and advisers of the Company are intended to be NQOs. 
  
 5.4 Subject to Section 6.3.3 with respect to ISOs, the Administrator may
approve the grant of Options or SARs under this Plan to persons who are expected to become employees, directors, consultants or advisers of the Company, but are not employees, directors, consultants or advisers at the date of approval. 

 

	6.	TERMS AND CONDITIONS OF OPTIONS AND SARS 

  
 Each Option and SAR granted under this Plan shall be subject to the terms and conditions set forth in Section 6.1. NQOs and SARs shall also be subject to
the terms and conditions set forth in Section 6.2, but not those set forth in Section 6.3. ISOs shall also be subject to the terms and conditions set forth in Section 6.3, but not those set forth in Section 6.2. SARs shall be subject to the terms
and conditions of Section 6.4. 
  
 6.1 Terms and Conditions to
Which All Options and SARs Are Subject. All Options and SARs granted under this Plan shall be subject to the following terms and conditions: 
  
 6.1.1 Changes in Capital Structure. Subject to Section 6.1.2, if the stock of the Company is changed by reason of a stock split,
reverse stock split, stock dividend, recapitalization, combination or reclassification, or if the Company effects a spin-off of the 

  

 3 

 
Company’s subsidiary, appropriate adjustments shall be made by the Administrator, in its sole discretion, in (a) the number and class of shares of stock
subject to this Plan and each Option and SAR outstanding under this Plan, and (b) the exercise price of each outstanding Option; provided, that the Company shall not be required to issue fractional shares as a result of any such adjustments.
Any adjustment, however, in an outstanding Option shall be made without change in the total price applicable to the unexercised portion of the Option but with a corresponding adjustment in the price for each share covered by the unexercised portion
of the Option. Adjustments under this Section 6.1.1 shall be made by the Administrator, whose determination as to the nature of the adjustments that shall be made, and the extent thereof, shall be final, binding, and conclusive. If an adjustment
under this Section 6.1.1 would result in a fractional share interest under an option or any installment, the Administrator’s decision as to inclusion or exclusion of that fractional share interest shall be final, but no fractional shares of
stock shall be issued under the Plan on account of any such adjustment. 
  
 6.1.2 Corporate Transactions. Except as otherwise provided in the applicable agreement, in the event of a Corporate Transaction (as defined below), the Administrator shall notify each holder of an Option or SAR
at least thirty (30) days prior thereto or as soon as may be practicable. To the extent not then exercised all Options and SARs shall terminate immediately prior to the consummation of such Corporate Transaction unless the Administrator determines
otherwise in its sole discretion; provided. however, that the Administrator, in its sole discretion, may (i) permit exercise of any Options or SARs prior to their termination, even if such Options or SARs would not otherwise have been
exercisable, and/or (ii) provide that all or certain of the outstanding Options and SARs shall be assumed or an equivalent Option or SAR substituted by an applicable successor corporation or entity or any Affiliate of the successor corporation or
entity. A “Corporate Transaction” means (i) a liquidation or dissolution of the Company; (ii) a merger or consolidation of the Company with or into another corporation or entity (other than a merger with a wholly-owned subsidiary); (iii) a
sale of all or substantially all of the assets of the Company; or (iv) a purchase or other acquisition of more than 50% of the outstanding stock of the Company by one person or by more than one person acting in concert. 
  
 6.1.3 Time of Option or SAR Exercise. Subject to
Section 5 and Section 6.3.4, an Option or SAR granted under the Plan shall be exercisable (a) immediately as of the effective date of the of the applicable agreement or (b) in accordance with a schedule or performance criteria as may be set by the
Administrator and specified in the applicable agreement. However, in no case may an Option or SAR be exercisable until a written agreement in form and substance satisfactory to the Company is executed by the Company and the grantee. 
  
 6.1.4 Grant Date. The date of grant of an Option or
SAR under the Plan shall be the effective date of the applicable agreement. 
  
 6.1.5 Non-Transferability of Rights. Except with the express written approval of the Administrator, which approval the Administrator is authorized to give only with respect to NQOs and SARs, no Option or SAR
granted under this Plan shall be assignable or otherwise transferable by the grantee except by will or by the laws of descent and distribution. During the life of the grantee, an Option or SAR shall be exercisable only by the grantee. 
  

 4 

 6.1.6 Payment. Except as provided below, payment in full, in cash, shall be made
for all stock purchased at the time written notice of exercise of an Option is given to the Company and the proceeds of any payment shall be considered general funds of the Company. The Administrator, in the exercise of its absolute discretion after
considering any tax, accounting and financial consequences, may authorize any one or more of the following additional methods of payment: 
  
 (a) Subject to the Sarbanes-Oxley Act of 2002, acceptance of the optionee’s full recourse promissory note for all or part of the
Option price, payable on such terms and bearing such interest rate as determined by the Administrator (but in no event less than the minimum interest rate specified under the Code at which no additional interest or original issue discount would be
imputed), which promissory note may be either secured or unsecured in such manner as the Administrator shall approve (including, without limitation, by a security interest in the shares of the Company); 
  
 (b) Subject to the discretion of the Administrator and the
terms of the stock option agreement granting the Option, delivery by the optionee of shares of Common Stock already owned by the optionee for all or part of the Option price, provided the fair market value (determined as set forth in Section 6.1.9)
of such shares of Common Stock is equal on the date of exercise to the Option price, or such portion thereof as the optionee is authorized to pay by delivery of such stock; 
  
 (c) Subject to the discretion of the Administrator, through the surrender of shares of Common Stock then
issuable upon exercise of the Option, provided the fair market value (determined as set forth in Section 6.1.9) of such shares of Common Stock is equal on the date of exercise to the Option price, or such portion thereof as the optionee is
authorized to pay by surrender of such stock; and 
  
 (d) By means of so-called cashless exercises as permitted under applicable rules and regulations of the Securities and Exchange Commission and the Federal Reserve Board. 
  
 6.1.7 Withholding and Employment Taxes. At the time of exercise and as a condition thereto, or at
such other time as the amount of such obligation becomes determinable, the grantee of an Option or SAR shall remit to the Company in cash all applicable federal and state withholding and employment taxes. Such obligation to remit may be satisfied,
if authorized by the Administrator in its sole discretion, after considering any tax, accounting and financial consequences, by the holder’s (i) delivery of a promissory note in the required amount on such terms as the Administrator deems
appropriate, (ii) tendering to the Company previously owned shares of Common Stock or other securities of the Company with a fair market value equal to the required amount, or (iii) agreeing to have shares of Common Stock (with a fair market value
equal to the required amount), which are acquired upon exercise of the Option or SAR, withheld by the Company. 
  
 6.1.8 Other Provisions. Each Option and SAR granted under this Plan may contain such other terms, provisions, and conditions not
inconsistent with this Plan as may be determined by the Administrator, and each ISO granted under this Plan shall include such 

  

 5 

 
provisions and conditions as are necessary to qualify the Option as an “incentive stock option” within the meaning of Section 422 of the Code.

  
 6.1.9 Determination of Value. For
purposes of this Plan, the fair market value of Common Stock or other securities of the Company shall be determined as follows: 
  
 (a) If the stock of the Company is listed on a securities exchange or is regularly quoted by a recognized securities dealer, and selling
prices are reported, its fair market value shall be the closing price of such stock on the date the value is to be determined, but if selling prices are not reported, its fair market value shall be the mean between the high bid and low asked prices
for such stock on the date the value is to be determined (or if there are no quoted prices for the date of grant, then for the last preceding business day on which there were quoted prices). 
  
 (b) In the absence of an established market for the stock,
the fair market value thereof shall be determined in good faith by the Administrator, with reference to the Company’s net worth, prospective earning power, dividend-paying capacity, and other relevant factors, including the goodwill of the
Company, the economic outlook in the Company’s industry, the Company’s position in the industry, the Company’s management, and the values of stock of other corporations in the same or a similar line of business. 
  
 6.1.10 Option and SAR Term. No Option or SAR shall be
exercisable more than 10 years after the date of grant, or such lesser period of time as is set forth in the applicable agreement (the end of the maximum exercise period stated in the agreement is referred to in this Plan as the “Expiration
Date”). 
  
 6.2 Terms and Conditions to Which Only NQOs
Are Subject. Options granted under this Plan which are designated as NQOs shall be subject to the following terms and conditions: 
  
 6.2.1 Exercise Price. The exercise price of an NQO shall be no less than the fair market value of the Common Stock on the date of
grant. 
  
 6.2.2 Termination of
Employment. Except as otherwise provided in the applicable agreement, if for any reason a grantee ceases to be employed by the Company or any of its Affiliates, Options that are NQOs and SARs held at the date of termination (to the extent then
exercisable) may be exercised in whole or in part at any time within ninety (90) days of the date of such termination (but in no event after the Expiration Date). For purposes of this Section 6.2.2, “employment” includes service as a
director, consultant or adviser. For purposes of this Section 6.2.2, a grantee’s employment shall not be deemed to terminate by reason of the grantee’s transfer from the Company to an Affiliate, or vice versa, or sick leave, military leave
or other leave of absence approved by the Administrator, if the period of any such leave does not exceed ninety (90) days or, if longer, if the grantee’s right to reemployment by the Company or any Affiliate is guaranteed either contractually
or by statute. 
  
 6.3 Terms and Conditions to Which Only ISOs
Are Subject. Options granted under this Plan which are designated as ISOs shall be subject to the following terms and conditions: 
  
 6.3.1 Exercise Price. The exercise price of an ISO shall not be less than the fair market value (determined in accordance with
Section 6.1.9) of the stock covered by the Option at the time the Option is granted. The exercise price of an ISO granted to any person who owns, directly or by attribution under the Code (currently Section 424(d)), stock possessing more than ten
percent (10%) of the total combined voting power of all classes of stock of the Company or of any Affiliate (a “Ten Percent Stockholder”) shall in no event be less than one hundred ten percent (110%) of the fair market value (determined in
accordance with Section 6.1.9) of the stock covered by the Option at the time the Option is granted. 
  

 6 

 6.3.2 Disqualifying Dispositions. If stock acquired by exercise of an ISO granted
pursuant to this Plan is disposed of in a “disqualifying disposition” within the meaning of Section 422 of the Code (a disposition within two (2) years from the date of grant of the Option or within one year after the issuance of such
stock on exercise of the Option), the holder of the stock immediately before the disposition shall promptly notify the Company in writing of the date and terms of the disposition and shall provide such other information regarding the Option as the
Company may reasonably require. 
  
 6.3.3
Grant Date. If an ISO is granted in anticipation of employment as provided in Section 5.4, the Option shall be deemed granted, without further approval, on the date the grantee assumes the employment relationship forming the basis for such
grant, and, in addition, satisfies all requirements of this Plan for Options granted on that date. 
  
 6.3.4 Term. Notwithstanding Section 6.1.10, no ISO granted to any Ten Percent Stockholder shall be exercisable more than five (5)
years after the date of grant. 
  
 6.3.5
Termination of Employment. Except as otherwise provided in the stock option agreement, if for any reason an optionee ceases to be employed by the Company or any of its Affiliates, Options that are ISOs held at the date of termination (to the
extent then exercisable) may be exercised in whole or in part at any time within ninety (90) days of the date of such termination (but in no event after the Expiration Date). For purposes of this Section 6.3.5, an optionee’s employment shall
not be deemed to terminate by reason of the optionee’s transfer from the Company to an Affiliate, or vice versa, or sick leave, military leave or other leave of absence approved by the Administrator, if the period of any such leave does not
exceed ninety (90) days or, if longer, if the optionee’s right to reemployment by the Company or any Affiliate is guaranteed either contractually or by statute. 
  
 6.4 Terms and Conditions Applicable Solely to SARs. In addition to the other terms and conditions applicable to SARs
in this Section 6, the holder shall be entitled to receive on exercise of an SAR only Common Stock at a fair market value equal to the benefit to be received by the exercise. 
  

	7.	MANNER OF EXERCISE 

  
 7.1 An optionee wishing to exercise an Option or SAR shall give written notice to the Company at its principal executive office, to the attention of the
officer of the Company designated by the Administrator, accompanied by payment of the exercise price and/or withholding taxes as provided in Sections 6.1.6 and 6.1.7. The date the Company receives 

  

 7 

 
written notice of an exercise hereunder accompanied by the applicable payment will be considered as the date such Option or SAR was exercised. 
  
 7.2 Promptly after receipt of written notice of exercise and the applicable
payments called for by Section 7.1, the Company shall, without stock issue or transfer taxes to the holder or other person entitled to exercise the Option or SAR, deliver to the holder or such other person a certificate or certificates for the
requisite number of shares of Common Stock. A holder or permitted transferee of an Option or SAR shall not have any privileges as a stockholder with respect to any shares of Common Stock to be issued until the date of issuance (as evidenced by the
appropriate entry on the books of the Company or a duly authorized transfer agent) of such shares. 
  

	8.	RESTRICTED STOCK 

  
 8.1 Grant or Sale of Restricted Stock. 
  
 8.1.1 No awards of restricted stock shall be granted under this Plan after ten (10) years from the date of adoption of this Plan by the
Board. 
  
 8.1.2 The Administrator may issue
shares under the Plan as a grant or for such consideration (including services, and, subject to the Sarbanes-Oxley Act of 2002, promissory notes) as determined by the Administrator. Shares issued under the Plan shall be subject to the terms,
conditions and restrictions determined by the Administrator. The restrictions may include restrictions concerning transferability, repurchase by the Company and forfeiture of the shares issued, together with such other restrictions as may be
determined by the Administrator. If shares are subject to forfeiture or repurchase by the Company, all dividends or other distributions paid by the Company with respect to the shares may be retained by the Company until the shares are no longer
subject to forfeiture or repurchase, at which time all accumulated amounts shall be paid to the recipient. All Common Stock issued pursuant to this Section 8 shall be subject to a purchase or grant agreement, which shall be executed by the Company
and the prospective recipient of the shares prior to the delivery of certificates representing such shares to the recipient. The purchase or grant agreement may contain any terms, conditions, restrictions, representations and warranties required by
the Administrator. The certificates representing the shares shall bear any legends required by the Administrator. The Administrator may require any purchaser of restricted stock to pay to the Company in cash upon demand amounts necessary to satisfy
any applicable federal, state or local tax withholding requirements. If the purchaser fails to pay the amount demanded, the Administrator may withhold that amount from other amounts payable by the Company to the purchaser, including salary, subject
to applicable law. With the consent of the Administrator in its sole discretion, a purchaser may deliver Common Stock to the Company to satisfy this withholding obligation. Upon the issuance of restricted stock, the number of shares reserved for
issuance under the Plan shall be reduced by the number of shares issued. 
  
 8.2 Changes in Capital Structure. In the event of a change in the Company’s capital structure, as described in Section 6.1.1, appropriate adjustments shall be made by the Administrator, in its sole
discretion, in the number and class of restricted stock subject to this 

  

 8 

 
Plan and the restricted stock outstanding under this Plan; provided, however, that the Company shall not be required to issue fractional shares
as a result of any such adjustments. 
  
 8.3 Corporate
Transactions. In the event of a Corporate Transaction, as defined in Section 6.1.2 hereof, to the extent not previously forfeited, all restricted stock shall be forfeited immediately prior to the consummation of such Corporate Transaction unless
the Administrator determines otherwise in its sole discretion; provided, however, that the Administrator, in its sole discretion, may remove any restrictions as to any restricted stock. The Administrator may, in its sole discretion,
provide that all outstanding restricted stock participate in the Corporate Transaction with an equivalent stock substituted by an applicable successor corporation subject to the restriction. 
  

	9.	EMPLOYMENT OR CONSULTING RELATIONSHIP 

  
 Nothing in this Plan or any Option granted hereunder shall interfere with or limit in any way the right of the Company or of any of its Affiliates to
terminate the employment, consulting or advising of any optionee or restricted stock holder at any time, nor confer upon any optionee or restricted stock holder any right to continue in the employ of, or consult or advise with, the Company or any of
its Affiliates. 
  

	10.	CONDITIONS UPON ISSUANCE OF SHARES 

  
 10.1 Securities Act. Shares of Common Stock shall not be issued pursuant to the exercise of an Option or the receipt of restricted stock unless the
exercise of such Option or such receipt of restricted stock and the issuance and delivery of such shares pursuant thereto shall comply with all relevant provisions of law, including, without limitation, the Securities Act of 1933, as amended (the
“Securities Act”). 
  
 10.2 Non-Compete
Agreement. As a further condition to the receipt of Common Stock pursuant to the exercise of an Option or the receipt of restricted stock, the optionee or recipient of restricted stock may be required not to render services for any organization,
or engage directly or indirectly in any business, competitive with the Company at any time during which (i) an Option is outstanding to such Optionee and for six (6) months after any exercise of an Option or the receipt of Common Stock pursuant to
the exercise of an Option and (ii) restricted stock is owned by such recipient and for six (6) months after the restrictions on such restricted stock lapse. Failure to comply with this condition shall cause such Option and the exercise or issuance
of shares thereunder and/or the award of restricted stock to be rescinded and the benefit of such exercise, issuance or award to be repaid to the Company. 
  

	11.	NON-EXCLUSIVITY OF THIS PLAN 

  
 The adoption of this Plan shall not be construed as creating any limitations on the power of the Company to adopt such other incentive arrangements as it
may deem desirable, including, without limitation, the granting of stock options other than under this Plan. 
  

 9 

	12.	MARKET STAND-OFF 

  
 Each optionee, holder of an SAR or recipient of restricted stock, if so requested by the Company or any representative of the underwriters in connection
with any registration of the offering of any securities of the Company under the Securities Act, shall not sell or otherwise transfer any shares of Common Stock acquired upon exercise of Options, SARs or receipt of restricted stock during the
180-day period following the effective date of a registration statement of the Company filed under the Securities Act; provided, however, that such restriction shall apply only to a registration statement of the Company which includes
securities to be sold on behalf of the Company to the public in an underwritten public offering under the Securities Act and the restriction period shall not exceed 90 days after the registration statement becomes effective. 
  

	13.	AMENDMENTS TO PLAN 

  
 The Board may at any time amend, alter, suspend or discontinue this Plan. Without the consent of an optionee, holder of an SAR or holder of restricted
stock, no amendment, alteration, suspension or discontinuance may adversely affect such person’s outstanding Option(s), SAR(s) or the terms applicable to restricted stock except to conform this Plan and ISOs granted under this Plan to the
requirements of federal or other tax laws relating to incentive stock options. No amendment, alteration, suspension or discontinuance shall require stockholder approval unless (a) stockholder approval is required to preserve incentive stock option
treatment for federal income tax purposes or (b) the Board otherwise concludes that stockholder approval is advisable. 
  

	14.	EFFECTIVE DATE OF PLAN; TERMINATION 

  
 This Plan shall become effective upon adoption by the Board; provided, however, that no Option or SAR shall be exercisable unless and until
written consent of the stockholders of the Company, or approval of stockholders of the Company voting at a validly called stockholders’ meeting, is obtained within twelve (12) months after adoption by the Board. If any Options or SARs are so
granted and stockholder approval shall not have been obtained within twelve (12) months of the date of adoption of this Plan by the Board, such Options and SARs shall terminate retroactively as of the date they were granted. Awards may be made under
this Plan and exercise of Options and SARs shall occur only after there has been compliance with all applicable federal and state securities laws. This Plan (but not Options and SARs previously granted under this Plan) shall terminate within ten
(10) years from the date of its adoption by the Board. Termination shall not affect any outstanding Options or SARs or the terms applicable to previously awarded restricted stock. 
  

 10Manufacturing Agreement

 Exhibit 10.1 
  
 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

 MANUFACTURING AGREEMENT 
  
 FOR 
  
 CLINICAL TRIAL AND COMMERCIAL SUPPLY 
  
 B E T W E E N: 
  
 CORAUTUS GENETICS INC. 
 a corporation incorporated under the laws of Delaware,

 having its corporate head office and principal place of business at 
 75 Fifth Street, NW, Suite 313, 
 Atlanta, GA 30308, USA 
 (hereinafter referred to as “Corautus”) 
  
 - and - 
  
 BOEHRINGER INGELHEIM AUSTRIA GmbH 
 a corporation incorporated under the laws of
the Federal Republic of Austria, 
 having its registered seat at 
 Dr. Boehringer-Gasse 5 – 11 
 A-1121 Vienna, Austria 
 (hereinafter referred to as “BI Austria”) 
  

 Page 1 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

 TABLE OF CONTENTS 
  

					
	1.	  	DEFINITIONS	  	8
			
	2.	  	PURPOSE AND SCOPE	  	12
			
	3.	  	DELIVERABLES OF CORAUTUS	  	14
			
	3.1	  	Documentation Transfer	  	14
			
	3.2	  	Material Transfer	  	14
			
	3.3	  	Assistance and Support by Corautus	  	14
			
	4.	  	EQUIPMENT	  	15
			
	4.1	  	Required Equipment	  	15
			
	4.2	  	Ownership and Rights to Possession	  	15
			
	4.3	  	Validation and Maintenance	  	16
			
	5.	  	MATERIALS	  	16
			
	5.1	  	CORAUTUS WCB	  	16
			
	5.2	  	Resins, Raw Materials and Storage Containers	  	17
			
	6.	  	BI AUSTRIA SERVICES	  	18
			
	6.1.	  	BI Austria Facilities	  	18
			
	6.2	  	BI Austria Documentation and Set-Up	  	18
			
	6.3	  	FEASIBILITY STUDY	  	19
			
	6.4	  	Method Transfer Services	  	19
			
	6.5	  	Establishment of Production Process for DRUG PRODUCT	  	19
			
	6.6	  	Implementation Batches	  	20
			
	6.7	  	Batches for Reference Standard and Clinical Trials	  	21

  

 Page 2 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

					
	6.8	  	Conformance Batches	  	21
			
	6.9	  	Labeling and Packaging	  	21
			
	6.10	  	Stability Studies	  	22
			
	7.	  	TIMETABLE AND INCENTIVES	  	22
			
	8.	  	DELAYED APPROVAL OF CLINICAL TRIALS	  	22
			
	9.	  	STERILITY DRUG SUBSTANCE	  	23
			
	10.	  	CLINICAL AND COMMERCIAL MANUFACTURE DURING PERIOD THREE	  	23
			
	10.1.	  	Product Supply	  	23
			
	10.2.	  	Preliminary Market Launch Date and Product Estimate	  	23
			
	10.3.	  	Minimum and Maximum Volume	  	24
			
	10.4.	  	Rolling Forecast	  	25
			
	10.5.	  	Packaging/Labeling by BI Austria	  	25
			
	10.6.	  	Warehousing at BI Austria Facilities	  	25
			
	10.7.	  	Release	  	26
			
	11.	  	SHIPMENT OF DRUG PRODUCT	  	26
			
	11.3	  	Drug Product Delivery and Delivery Documents	  	26
			
	11.4	  	Ownership and Insurance Liabilities	  	27
			
	12.	  	DOCUMENTATION	  	27
			
	13.	  	QUALITY CONTROL AND QUALITY MANAGEMENT	  	28
			
	13.1	  	Validation Services	  	28
			
	13.2	  	Quality Control	  	29
			
	13.3	  	Quality Management	  	29
			
	13.4	  	Change Control	  	30

  

 Page 3 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

					
	14.	  	REGULATORY	  	30
			
	14.1	  	Regulatory Compliance	  	30
			
	14.2	  	Manufacturing Audits and Regulatory Inspections	  	30
			
	14.3	  	Regulatory Filings	  	31
			
	15.	  	CORAUTUS’ ACCESS TO BI AUSTRIA FACILITIES	  	31
			
	16.	  	DISPUTE RESOLUTION FOR NON-CONFORMING DRUG PRODUCT	  	32
			
	16.1	  	Rejection Procedure / Confirmatory Third PARTY Testing	  	32
			
	16.2	  	Replacement	  	33
			
	16.3	  	Stock Build-up	  	33
			
	16.4	  	Unforeseeable Quality Problems	  	33
			
	17.	  	PRICES AND PAYMENTS	  	34
			
	17.1	  	Prices for the SERVICES	  	34
			
	17.2	  	Prices for DRUG PRODUCT during PERIOD THREE	  	34
			
	17.3	  	Taxes	  	35
			
	17.4	  	Currency	  	35
			
	17.5	  	Terms of Payment	  	35
			
	17.6	  	Accrual Accounting	  	36
			
	18.	  	PROJECT MANAGEMENT, MEETINGS AND PLANNING	  	36
			
	19.	  	CONFIDENTIAL INFORMATION	  	37
			
	20.	  	INTELLECTUAL PROPERTY	  	39
			
	20.1.	  	Ownership of INTELLECTUAL PROPERTY	  	39
			
	20.2.	  	Ownership of INVENTIONS	  	39
			
	20.3.	  	License Grants	  	39

  

 Page 4 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

					
	 21.
	  	PROSECUTION	  	39
			
	 22.
	  	INFRINGEMENT OF PARTIES CONFIDENTIAL INFORMATION AND INTELLECTUAL PROPERTY	  	40
			
	 23.
	  	INDEMNIFICATION AND LIABILITY	  	40
			
	 23.1
	  	Indemnification of BI Austria by Corautus against third party claims	  	40
			
	 23.2
	  	Indemnification of Corautus by BI Austria against third party claims	  	41
			
	 23.3
	  	Notification of third party claims	  	41
			
	 23.4
	  	Limitation of liability for third party claims	  	42
			
	 23.5
	  	Liability for non-third party claims	  	42
			
	 23.6
	  	Disclaimer of consequential damages	  	42
			
	 23.7
	  	Burden of proof	  	42
			
	 24.
	  	INSURANCE	  	42
			
	 25.
	  	REPRESENTATIONS AND WARRANTIES	  	43
			
	 25.1.
	  	Representations and Warranties by BI Austria	  	43
			
	 25.2.
	  	Representations and Warranties by Corautus	  	44
			
	 26.
	  	TERM	  	44
			
	 27.
	  	TERMINATION	  	44
			
	 27.1.
	  	Termination by either PARTY	  	44
			
	 27.2
	  	Termination by Corautus	  	45
			
	 27.3
	  	Termination by BI Austria	  	46
			
	 28.
	  	MITIGATION	  	47
			
	 29.
	  	EFFECT OF TERMINATION OR EXPIRATION	  	47
			
	 30.
	  	GOVERNING LAW AND ARBITRATION	  	48

  

 Page 5 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

					
	 31.
	  	WAIVER	  	49
			
	 32.
	  	FORCE MAJEURE	  	49
			
	 33.
	  	SEVERABILITY	  	49
			
	 34.
	  	NOTICES	  	50
			
	 35.
	  	ASSIGNMENT AND ENUREMENT	  	50
			
	 36.
	  	INTEGRATION	  	52
			
	 37.
	  	PUBLICITY	  	52

  

 Page 6 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

 OUTLINE 
  
 MANUFACTURING AGREEMENT 
  
 FOR 
  
 CLINICAL TRIAL AND COMMERCIAL SUPPLY 
  
 This AGREEMENT is effective as of November 1, 2004 (the “EFFECTIVE DATE”) by and between Corautus and BI Austria. 
  
 WHEREAS, Corautus has licensed from Human Genome Sciences (HGS) the vascular
endothelial growth factor-2 gene, referred to as VEGF-2, and has produced proprietary naked plasmid DNA encoding for VEGF-2, including plasmid DNA sometimes referred to as phVEGF-2 or pVGI.1(VEGF2). Such plasmid product is used for gene therapy
applications in vascular diseases; and 
  
 WHEREAS, BI Austria possesses a
proprietary production process for plasmid DNA drug substance and manufactures plasmid DNA drug substance under GMP conditions suitable for clinical trials and commercial sale in the U.S., Europe and elsewhere; and 
  
 WHEREAS, Corautus desires BI Austria to perform certain development and optimization
services to establish a production process for drug substance using the BI Austria proprietary production process; and 
  
 WHEREAS, BI Austria desires to manufacture drug product for Corautus in accordance with Corautus’ requirements and Corautus is desirous of having BI Austria
manufacture drug substance for formulating and finishing into drug product for clinical trials and commercial sale; and 
  
 WHEREAS, Corautus has transferred or will transfer to BI Austria, and BI Austria has received and will receive from Corautus, certain quantities of biological
materials and related documentation for such limited purposes pursuant to the terms and conditions set forth in this AGREEMENT; 
  
 WHEREAS BI Austria, as agreed with Corautus, has conducted a certain feasibility study at small scale comparing the Corautus’ HGS clone with a particular BI
Austria (transformed) host strain (“the FEASIBILITY STUDY”); and 
  
 WHEREAS Corautus expects to file a BLA for the approval for marketing and sale of drug product in the US and other territories and requires certain quantities of drug product according to certain product specifications. Based on current
project planning, commercial sale in the US is targeted to begin ** these dates are non-binding and for orientation
purposes only; and 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 7 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

 WHEREAS, Corautus and BI Austria have executed a Confidential Disclosure AGREEMENT dated 4 December 2003
intended to cover the discussions leading to the Material Transfer AGREEMENT dated 13 July 2004 (the “MATERIAL TRANSFER AGREEMENT”) and to this AGREEMENT. 
  
 NOW THEREFORE in consideration of the foregoing premises, the mutual covenants and obligations hereinafter contained, and other good and
valuable consideration, receipt and sufficiency of which is hereby acknowledged, THE PARTIES AGREE AS FOLLOWS: 
  

	1.	DEFINITIONS 

  

	1.1	AFFILIATE means any entity that directly or indirectly owns, is owned by, or is under common ownership with, Corautus or BI Austria, where “own” or “ownership”
means possession or control of at least 50% of the voting capital shares or voting rights of a corporation or a comparable equity interest in any other type of entity. 

  

	1.2	AGENT means any person who is not an employee of either PARTY and who renders services for one of the PARTIES in the field of the manufacture, testing, use or sale of the DRUG
PRODUCT. Use of an AGENT by a PARTY requires the other PARTY’s prior consent in writing, such consent not to be unreasonably withheld. The AGENT consented to shall enter into a separate confidentiality agreement with the other PARTY.

  

	1.3	AGREEMENT means this Manufacturing AGREEMENT for Clinical Trial and Commercial Supply. 

  

	1.4	BATCH RECORD means the complete written record of the history of the batch and its production thereof as required under GMP and in accordance with the MASTER BATCH RECORD.

  

	1.5	BLA means the Biologics License Application for DRUG PRODUCT. 

  

	1.6	CMC means the chemistry, manufacturing and controls content of a submission for registration to HEALTH AUTHORITIES. 

  

	1.7	COA means the Certificate of Analysis prepared for the DRUG SUBSTANCE or DRUG PRODUCT as applicable, listing the analytical test performed, the limits and results of each test. This
document shall include the name of the DRUG SUBSTANCE or DRUG PRODUCT as applicable, the batch number, the date of manufacture and the expiry date, if appropriate.  

  

	1.8	COC means the Certificate of Compliance prepared for the DRUG SUBSTANCE or DRUG PRODUCT as applicable confirming compliance with GMP regulations and signed by BI Austria’s
Qualified Person and Quality Management which terms are defined in the QUALITY AGREEMENT. 

  

 Page 8 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	1.9	CONFIDENTIAL INFORMATION means any information disclosed by a PARTY or an AFFILIATE or AGENT of such PARTY to the other PARTY, its AFFILIATE or AGENT, which information includes,
but is not limited to: DRUG PRODUCT; the processes and methods employed in the manufacture of DRUG PRODUCT; BATCH RECORDS, SPECIFICATIONS; information related to the facilities at BI Austria; information related to plasmid production processes or to
any products produced at the BI Austria facilities; any prices and costs of BI Austria; regulatory filings for the DRUG PRODUCT; Corautus’ and BI Austria’s manufacturing, business and regulatory plans and strategies; and other data and
information disclosed or exchanged under this AGREEMENT. Any INVENTION of a PARTY as set forth in Section 1.26 shall also be regarded as CONFIDENTIAL INFORMATION of such PARTY. 

  

	1.10	CONFIRMATORY BATCHES means the two (2) **
working volume fermentation batches and small scale purification batches pursuant to Section 6.3.2, which have been completed. 

  

	1.11	CONFORMANCE BATCHES means three (3) batches to carry out the process validation and which will form part of regulatory submissions. 

  

	1.12	CORAUTUS WCB means the GMP working cell bank of viable E. coli containing the original plasmid construct pVGI.1(VEGF2) as prepared by Corautus, described in Exhibit 1 and
provided to BI Austria by Corautus. 

  

	1.13	DATE AVAILABLE FOR DELIVERY means the date on which Corautus requests that DRUG PRODUCT be available for shipment. 

  

	1.14	DRUG SUBSTANCE means bulk of the vascular endothelial growth factor-2 gene referred to as VEGF-2 and proprietary naked plasmid DNA encoding for VEGF-2, including the plasmid DNA
sometimes referred to as phVEGF-2 or pVGl.1(VEGF2) as defined in Exhibit 2 and produced using the SELECTED WCB and BI Austria’s proprietary production process. 

  

	1.15	DRUG SUBSTANCE SPECIFICATIONS means the testing SPECIFICATIONS which are attached in Exhibit 3, and mutually amended from time to time by the PARTIES in accordance with Change
Control, as defined in the Quality AGREEMENT. 

  

	1.16	DRUG PRODUCT means a finished product consisting of formulated DRUG SUBSTANCE filled into designated containers, as described in Exhibit 4, or shall mean a finished product of
formulation buffer filled into the designated containers (placebo). 

  

	1.17	DRUG PRODUCT SPECIFICATIONS means the testing SPECIFICATIONS for DRUG PRODUCT as set forth in Exhibit 5, as may be revised from time to time by the PARTIES in accordance with Change
Control. 

  

	1.18	EMEA means the European Agency for the Evaluation of Medicinal Products and any successor agency or entity having similar jurisdiction. 

  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 9 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	1.19	FDA means the United States Food and Drug Administration or any successor agency having similar jurisdiction. 

  

	1.20	FEASIBILITY STUDY means the feasibility study as set forth in Exhibit 6 in order to select an E.coli host and fermentation process mode for the manufacture of DRUG SUBSTANCE.

  

	1.21	FINAL RELEASE means the release of DRUG PRODUCT by Corautus for use in clinical trials or for commercial use in accordance with Corautus’ standard operating procedures. Final
Release signifies that the DRUG PRODUCT has been produced using approved processes, in compliance with appropriate regulations, and meets the established SPECIFICATIONS, as determined by Corautus’ review of all appropriate documentation.

  

	1.22	GMP means current Good Manufacturing Practices pursuant to (a) EEC Directive 91/356/EEC of 13 June 1991, (b) the EC Guide to Good Manufacturing Practice for Medicinal Products (c)
the U.S. Federal Food, Drug and Cosmetics Act as amended (21 USC 301 et seq.), (d) relevant U.S. regulations set forth in Title 21 of the U.S. Code of Federal Regulations (including Parts 11, 210, and 211), and (f) any applicable European
and/or U.S. laws, regulations or respective guidance documents subsequently established. 

  

	1.23	HEALTH AUTHORITIES mean all regulatory authorities having jurisdiction over the manufacture, use and/or sale of the DRUG PRODUCT in the TERRITORY, including but not limited to the
EMEA or the FDA. 

  

	1.24	IMPLEMENTATION BATCHES mean the two (2) BATCHES of DRUG SUBSTANCE and/or DRUG PRODUCT to technically implement the production process into the BI Austria GMP plant.

  

	1.25	INTELLECTUAL PROPERTY means patents, trade secrets, trade marks, service marks, registered designs, lab notebooks, applications for any of the foregoing, trade and business names,
unregistered trade marks and service marks, copyrights, rights in designs, inventions, know-how, rights under licenses, consents, orders, statutes or otherwise in relation to any such rights, and rights of the same or similar effect or nature, in
any part of the world. 

  

	1.26	INVENTION shall mean any invention, discovery or know-how, whether patentable or not, made or conceived by either PARTY, arising as a direct result of work performed under this
AGREEMENT. 

  

	1.27	MANUFACTURER RELEASE means BI Austria’s release of a batch. 

  

	1.28	MASTER BATCH RECORD means the master production instructions for manufacture of a batch. 

  

	1.29	MCB means Corautus GMP Master Cell Bank. 

  

 Page 10 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	1.30	METHOD TRANSFER SERVICES mean services provided by BI Austria in accordance with Section 6.4. 

  

	1.31	PARTY and PARTIES means Corautus or BI Austria, or both, as applicable. 

  

	1.32	PERIOD ONE means the period of time commencing when any Services are first performed under this AGREEMENT and ending at the completion of the IMPLEMENTATION BATCHES.

  

	1.33	PERIOD TWO means the period of time commencing with the GMP production of the reference standard and ending at the completion of the CONFORMANCE BATCHES. 

 

	1.34	PERIOD THREE means the period of time commencing after the completion of the CONFORMANCE BATCHES through the termination of this AGREEMENT. 

  

	1.35	PURCHASE ORDER means a written and signed notice provided by Corautus stating the required amount of DRUG PRODUCT (which amount must be within the purchasing obligation of Corautus
as given in the Red Zone of the then current Rolling Forecast) including date and address of delivery, the invoicing address, and contact details of persons to be notified in the event of shipment issues. 

  

	1.36	QUALITY AGREEMENT means the agreement on all quality procedures, aspects and responsibilities of the PARTIES related to the DRUG PRODUCT, a copy of which is attached as Exhibit 25
to this AGREEMENT. 

  

	1.37	SELECTED WCB means the GMP working cell bank manufactured from the E.coli host cell selected as result of the FEASIBILITY STUDY; such SELECTED WCB shall contain the
E.coli host cell (with the plasmid incorporated therein) and used for manufacture of the DRUG PRODUCT. 

  

	1.38	SERVICES mean the services to be performed by BI Austria in connection with the process establishment and manufacture of the DRUG PRODUCT, and preparing BI Austria to be approved by
the HEALTH AUTHORITIES as a GMP manufacturer of DRUG PRODUCT, as further described in Exhibit 7. 

  

	1.39	SOPs mean written standard operating procedures established, or to be established, by BI Austria and employed in the production, quality control, quality assurance, warehousing,
labeling and packaging, among other things. 

  

	1.40	SPECIFICATIONS mean numerical limits, ranges or other acceptance criteria for which the raw materials, DRUG SUBSTANCE, DRUG PRODUCT, intermediates, or the process of making the DRUG
PRODUCT, must conform to in order for the DRUG PRODUCT to be acceptable for its intended use. 

  

 Page 11 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	1.41	STABILITY STUDIES mean all studies necessary to assess the stability characteristics of intermediates, DRUG SUBSTANCE or DRUG PRODUCT which shall be used in determining appropriate
storage conditions and expiration dates. 

  

	1.42	TERRITORY means the United States and Europe. Countries to be defined as Europe are listed on Exhibit 8. 

  

	1.43	TESTING SPECIFICATIONS means a specific master document that lists the testing parameters, references to analytical procedures and their SPECIFICATIONS; types of TESTING
SPECIFICATIONS include but are not limited to the WCB, in-process controls, DRUG SUBSTANCE, DRUG PRODUCT and raw materials. 

  

	1.44	VALIDATION means documented evidence which provides a high degree of assurance that a specific process, activity, piece of equipment, SOP or other consumable required or used in the
manufacture of DRUG PRODUCT will consistently meet its pre-determined and expected results. 

  

	1.45	VALIDATION SERVICES means any VALIDATION services required of BI Austria in the manufacture of DRUG PRODUCT. 

  

	2.	PURPOSE AND SCOPE 

  

	2.1	This AGREEMENT is intended to provide the structure under which the long-term clinical and/or commercial manufacturing of DRUG PRODUCT shall be performed for Corautus by BI Austria.
The SERVICES and commercial manufacturing will be performed in three time periods: PERIOD ONE, PERIOD TWO and PERIOD THREE. 

  

	2.2	Corautus desires BI Austria to apply BI Austria’s independently developed proprietary manufacturing technology for the manufacture of DRUG SUBSTANCE at BI Austria’s GMP
facilities in Vienna, Austria. BI Austria has performed a FEASIBILITY STUDY in order to select an E.coli host and fermentation process mode for the manufacture of DRUG SUBSTANCE. The PARTIES assume that the WCB for the manufacture of DRUG
SUBSTANCE is compatible to BI Austria’s production process, and that fermentation is scaleable to 220 L working volume. BI Austria’s patent estate with respect to BI Austria’s manufacturing technology is set forth in Exhibit 9.

  

	2.3	Corautus physically possesses and owns or licenses all ownership rights to the respective GMP MCB and CORAUTUS WCB provided by Corautus to BI Austria. Corautus’ patent estate
with respect to the GMP WCB, the DRUG SUBSTANCE and the DRUG PRODUCT which is relevant to this AGREEMENT is referenced in Exhibit 10. 

  

 Page 12 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	2.4	The DRUG SUBSTANCE was previously produced by HGS for Corautus at a 750 L scale with a fermentation expression rate of about 30 mg DRUG SUBSTANCE per liter fermentation broth.

  

	2.5	Besides DRUG SUBSTANCE, BI Austria shall also manufacture DRUG PRODUCT in its pharmaceutical technology unit whereby the batch records of Corautus’ former contract manufacturer
for fill & finish shall form the basis for the batch records to be compiled by BI Austria and which shall be approved by Corautus for GMP batches. 

  

	2.6	Each of the PARTIES will in good faith and in accordance with the project timelines for PERIOD ONE and PERIOD TWO as set out in Exhibit 11 initiate and complete its respective tasks
for the establishment of a manufacturing process for DRUG PRODUCT provided, however, that the project timelines are subject to revision under Section 7.2 of this AGREEMENT. 

  

	2.7	The PARTIES have negotiated and executed a QUALITY AGREEMENT, a copy which is attached as Exhibit 25. 

  

	2.8	Through the end of PERIOD ONE and PERIOD TWO Corautus in its function as the sponsor for the clinical development of DRUG PRODUCT shall provide BI Austria with commercially
reasonable support necessary for the establishment and validation of a manufacturing process for DRUG PRODUCT. During PERIOD THREE Corautus shall inform BI Austria without unreasonable delay of any circumstances it becomes aware of which may have an
influence on the manufacture of DRUG PRODUCT. Corautus quality obligations are set forth in detail in the QUALITY AGREEMENT. 

  

	2.9	BI Austria will manufacture DRUG SUBSTANCE and DRUG PRODUCT for Corautus during PERIOD THREE as more particularly described in Section 10 hereof. 

  

	2.10	Countries Covered 

  
 In the event DRUG PRODUCT shall be supplied to countries other than the TERRITORY, the PARTIES shall in good faith negotiate modifications of the
PARTIES’ rights and obligations stipulated in this AGREEMENT in order to comply with the applicable regulatory requirements in such countries. 
  

	2.11	Exhibits that are attached hereto are incorporated in, and are deemed to be an integral part, of this AGREEMENT. Exhibits may be amended and additional exhibits may be added from
time to time after execution of this AGREEMENT if so agreed on in writing by the PARTIES. 

  

 Page 13 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	3.	DELIVERABLES OF CORAUTUS 

  

	3.1	Documentation Transfer 

  

	3.1.1	Corautus shall supply copies of documentation and/or records and any other documentation and/or records reasonably requested by BI Austria which are necessary for establishment of
the manufacturing process and for GMP manufacture of DRUG PRODUCT. 

  

	3.1.2	The documents supplied by Corautus as of the EFFECTIVE DATE to enable BI Austria to provide the SERVICES are set forth in Exhibit 12. 

  

	3.2	Material Transfer 

  

	3.2.1	Corautus shall provide BI Austria with WCB vials, samples of DRUG PRODUCT, reference standard, reagents for analytical testing not commercially available and any other material in
such reasonable amounts and at such times as agreed by the Project Team (as defined on Exhibit 21 of this AGREEMENT). 

  

	3.2.2	Corautus shall also supply BI Austria with such available material as is reasonably necessary for a comparison study comparing the DRUG PRODUCT manufactured at Corautus’
current manufacturer and the DRUG PRODUCT manufactured at BI Austria. 

  

	3.2.3	The material supplied by Corautus as of the EFFECTIVE DATE, and which is to be supplied, is set forth in Exhibit 13. 

  

	3.3	Assistance and Support by Corautus 

  

	3.3.1	During PERIOD ONE and PERIOD TWO Corautus shall use good faith reasonable commercial efforts to make relevant Corautus personnel available by telephone and e-mail for technical
assistance to BI Austria as reasonably requested by BI Austria in writing to facilitate BI Austria’s implementation and validation of the production process of DRUG SUBSTANCE and/or DRUG PRODUCT. BI Austria will provide advance notice to
Corautus regarding its desire to have access to Corautus personnel. 

  

	3.3.2	Corautus agrees that it will on an ongoing basis update its SPECIFICATIONS or other instructions to BI Austria so that they conform and comply with all legal and regulatory
requirements which both (a) apply to the clinical development or commercialization of gene therapy products and (b) affect the manufacture of the DRUG PRODUCT. Corautus will have these obligations for those portions and only those portions of the
TERRITORY in which Corautus intends to conduct clinical trials with or sell the Drug Product then being manufactured. 

  

	3.3.3	Corautus shall perform in a timely manner its obligations reflected in this AGREEMENT. 

  

 Page 14 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	4.	EQUIPMENT 

  

	4.1	Required Equipment 

  
 All general manufacturing and QC testing facilities for plasmid DNA production shall be established and maintained by BI Austria. However, Corautus shall
pay for the following equipment, which equipment will be the property of BI Austria. BI Austria will explore and identify the best possible supplier of the equipment. Based on BI Austria enquiries the PARTIES shall agree on the equipment to be
purchased. This equipment will be dedicated for the manufacture of DRUG PRODUCT. The maximum cost for the equipment to be purchased under this section shall not exceed the amounts shown for such equipment in Exhibit 7 of this AGREEMENT. 

 
 ** 
  

	4.1.1	If other equipment is needed specifically for the production or Quality Control of DRUG PRODUCT, BI Austria shall obtain Corautus’ prior written approval for the purchase of
such equipment and Corautus shall pay for such equipment in such amount as Corautus shall have approved in writing. BI Austria shall own such equipment, which equipment BI Austria will not use in the production or Quality Control of other products.

  

	4.1.2	If any additional equipment is used in the production of DRUG PRODUCT, including Quality Control, under this AGREEMENT or the QUALITY AGREEMENT, other than as specified in Sections
4.1. and 4.1.1., BI Austria shall be responsible at its own expense for purchasing, obtaining, validating, calibrating and implementing such equipment and BI Austria shall own such equipment. 

  

	4.2	Ownership and Rights to Possession 

  

	4.2.1	BI Austria shall own the equipment purchased by Corautus pursuant to Sections 4.1. and 4.1.1 but will not permit the equipment to be subject to any liens or encumbrances. Upon
expiry or termination of this AGREEMENT by Corautus for any reason, provided Corautus pays all sums owed in connection with such expiration or termination, and for a period of 180 days thereafter, Corautus has the right for 1.00 Euro on at least 30
days advance notice to purchase, take possession of, and remove from BI Austria’s facility any or all of the equipment that Corautus originally purchased. Upon receipt of such notice, BI Austria will assemble and appropriately pack for shipment
at Corautus’ costs all of the equipment purchased by Corautus pursuant to such notice and make same available at BI Austria ‘s facility, INCOTERM 2000 EXW (“ex works”) for pickup by a carrier selected by Corautus.

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 15 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	4.3	Validation and Maintenance 

  

	4.3.1	BI Austria shall be responsible for setting-up, calibrating, cleaning, qualifying, and maintaining all equipment required in the production of DRUG PRODUCT. Corautus shall pay BI
Austria the costs for qualification of the DRUG PRODUCT-dedicated equipment, which cost is included in the maximum cost for such equipment set forth on Exhibit 7. 

  

	4.3.2	BI Austria is entitled to charge to Corautus a one-time surcharge ** of the purchase price of DRUG PRODUCT-dedicated equipment described above in Sections 4.1
and 4.1.1. for purchasing, installing, calibrating, insuring and maintaining such DRUG PRODUCT-dedicated equipment during the term of the AGREEMENT. BI Austria shall be solely responsible for (a) reasonably maintaining the DRUG PRODUCT-dedicated
equipment, (b) repairing the DRUG PRODUCT-dedicated equipment as a result of ordinary and intended use of such equipment for the purposes of this AGREEMENT, (c) protecting such equipment from cross contamination with other products and (d) insuring
for its replacement cost against loss of such DRUG PRODUCT-dedicated equipment. In the event that despite all reasonable maintenance and ordinary and intended use of such DRUG PRODUCT-dedicated equipment an irreparable damage occurs, it will be
Corautus’ responsibility to replace such DRUG PRODUCT-dedicated equipment; provided, however, that BI Austria shall be solely responsible for costs to replace or repair any DRUG PRODUCT-dedicated equipment that is damaged due to (a) any
abnormal or unintended uses of such equipment, (b) any accident, fire, flood or other incident for which BI Austria’s insurance provides coverage, or (c) the failure to reasonably maintain the DRUG PRODUCT-dedicated equipment. The above one
time surcharge ** is included in the maximum costs for such equipment set forth in Exhibit 7.

  

	5.	MATERIALS 

  

	5.1	CORAUTUS WCB 

  

	5.1.1	Corautus shall provide the CORAUTUS WCB together with a certificate of analysis and a characterization report certifying fitness of the WCB for GMP production purposes.

  

	5.1.2	BI Austria shall conduct incoming tests for viability, identity, plasmid retention, limited bacteriophage testing and purity. BI Austria shall issue a COA certifying the test
results and compliance with SPECIFICATIONS and shall use such compliant WCB for the manufacture of DRUG PRODUCT. BI Austria will notify Corautus if the WCB is not satisfactory according to the incoming tests and can not be used for the manufacture
of DRUG PRODUCT. BI Austria will maintain records of usage of the WCB and will inform Corautus of needs for additional quantities or changes in characteristics thereof in a timely manner for use in any subsequent production.

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 16 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	5.1.3	Ownership and Insurance 

  
 Subject to Section 2.3, Corautus shall grant to BI Austria the non-exclusive right to use the MCB and/or WCB solely for the purposes of performing its
obligation under this AGREEMENT. For greater clarity, BI Austria acquires hereunder no ownership, license or security interest rights in the WCB and the corresponding MCB beyond the limited use license granted for production of DRUG PRODUCT under
this AGREEMENT. 
  
 BI Austria shall not transfer the WCB or the
corresponding MCB to any third party without the prior written permission of Corautus, and any unused quantities at the termination or expiration of the AGREEMENT shall be destroyed or returned to Corautus at Corautus’ request.

  
 BI Austria shall be responsible for maintaining such CORAUTUS
WCB and the corresponding MCB aliquots as provided by Corautus and stored at the BI Austria’s facilities. In the event such aliquots are destroyed while in BI Austria’s possession, BI Austria shall pay the replacement costs for such MCB or
WCB aliquots. 
  

	5.1.4	Handling and Storage 

  
 BI Austria shall be responsible for handling and storage of the CORAUTUS WCB provided by Corautus at BI Austria’s facilities. The storage shall be in
vapor phase in a liquid nitrogen tank. 
  

	5.2	Resins, Raw Materials and Storage Containers 

  

	5.2.1	BI Austria shall purchase all resins, raw materials and storage containers required for the manufacture and storage of DRUG PRODUCT. 

  

	5.2.2	It is acknowledged that BI Austria has established and qualified suppliers for resins, raw materials and storage containers and the PARTIES shall mutually agree on the respective
SPECIFICATIONS. Corautus may review the vendor qualification program / documentation in the course of the annual audit. 

  

	5.2.3	During PERIOD ONE and PERIOD TWO BI Austria will charge the following flat rate for services related to ordering, release testing, storage and weighing: 

  

			
	Flat Fee	 	in Euro
	per raw material or per consumable	 	**
	per resin	 	**

  
 These charges are
included in the respective estimates for raw materials given in Exhibit 7. 
  
 For PERIOD THREE the flat fee for raw materials is included in the price per gram or price per vial. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 17 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	6.	BI Austria SERVICES 

  
 The SERVICES to be performed by BI Austria during PERIOD ONE and PERIOD TWO are set forth in Exhibit 7. All such tasks deal with the development,
establishment and registration of the manufacturing process for DRUG PRODUCT. Due to the biological nature of the process and because DRUG PRODUCT is still in clinical development both PARTIES should adhere to the timelines set forth in Exhibit 11
as much as possible, but if changes are necessary, such changes shall be mutually agreed by both PARTIES. At the date of execution of this AGREEMENT, it is agreed by the PARTIES that, subject to the following provisions of this Section 6, the
manufacture of the CONFORMANCE BATCHES shall not commence prior to **. Notwithstanding the foregoing, Corautus may, with at least six (6) months prior notice in writing to BI Austria, delay the commencement of the CONFORMANCE
BATCHES. Such delay by Corautus shall only be permitted twice. In the event Corautus notifies BI Austria in writing that it is considering delaying the CONFORMANCE BATCHES (such notification to be given in writing no later than thirty (30) calendar
days before the aforementioned six-month notice period begins), BI Austria shall inform Corautus within fifteen (15) calendar days of receipt of such notice of possible alternative commencement dates in the event Corautus actually delays the
commencement of the CONFORMANCE BATCHES. The commencement date of such re-scheduled CONFORMANCE BATCHES must be mutually agreed. 
  

	6.1.	BI Austria Facilities 

  

	6.1.1	BI Austria shall be manufacturing DRUG PRODUCT at its facilities at Dr. Boehringer-Gasse 5 – 11, A-1121 Vienna, Austria. A description of the facilities showing the areas
designated for manufacture of DRUG PRODUCT are set out in Exhibit 14 attached. 

  

	6.1.2	BI Austria’s facilities shall have, and BI Austria shall continuously maintain, all required authorizations and permits necessary for the manufacture of DRUG PRODUCT for
clinical trials and commercial sale for use in humans. 

  

	6.1.3	For said facilities, BI Austria has established, or shall establish as necessary, GMP compliant rules concerning clothing, hygiene, personnel and material flow, safety, and
observations of SOPs. 

  

	6.2	BI Austria Documentation and Set-Up 

  

	6.2.1	BI Austria shall study the relevant documentation provided by Corautus. 

  

	6.2.2	BI Austria shall draft all necessary documentation, including SPECIFICATIONS, MASTER BATCH RECORD and SOPs required for the manufacture of DRUG PRODUCT, taking into account the
documentation supplied by Corautus. The documentation listed in Exhibit 15 shall be reviewed and approved by Corautus. Any additional documentation generated by BI Austria under this AGREEMENT shall be reviewed, approved, and supplied to
Corautus, as the PARTIES may agree. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 18 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	6.3	FEASIBILITY STUDY 

  

	6.3.1	BI Austria has conducted a FEASIBILITY STUDY as set forth in Exhibit 6 in order to select an E.coli host and fermentation process mode for the manufacture of DRUG SUBSTANCE.
Prior to the performance of the ** CONFIRMATORY BATCHES the PARTIES agreed upon the host best suited for fermentation of the of DRUG SUBSTANCE (the “SELECTED WCB”) and on the fed-batch
mode to be applied for fermentation. 

  

	6.3.2	As the DRUG SUBSTANCE from the ** CONFIRMATORY BATCHES is of experimental nature and does not meet GMP requirements, Corautus warrants that it shall not use such DRUG SUBSTANCE in
humans. 

  

	6.4	Method Transfer Services 

  

	6.4.1	The BI Austria plasmid DNA analytical methods for testing of DRUG SUBSTANCE and DRUG PRODUCT shall be applied as far as applicable. 

  

	6.4.2	BI Austria shall perform certain experiments to evaluate the feasibility of the BI Austria methods for DRUG SUBSTANCE and DRUG PRODUCT. 

  

	6.4.3	BI Austria shall provide to Corautus appropriate METHOD TRANSFER SERVICES for two (2) methods, i.e. the RNA and the Quantitative Potency assays as agreed to by the PARTIES in
separate written protocols, including documentation and implementation of both aforementioned analytical methods for in-process and DRUG PRODUCT release testing. The pricing contained in Exhibit 16 includes the cost of all two assays.

  

	6.4.4	Costs for method transfer are defined in Exhibit 16. 

  

	6.5	Establishment of Production Process for DRUG PRODUCT 

  

	6.5.1	Corautus requests that BI Austria shall establish a fermentation and purification process for DRUG SUBSTANCE using the SELECTED WCB and BI Austria’s proprietary production
technology for plasmid DNA products at a 220 L fermentation scale. 

  

	6.5.2	For the manufacture of DRUG PRODUCT BI Austria shall apply a fill and finish process which is based on the process applied at Corautus’ former contract manufacturer for fill
and finish. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 19 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	6.6	Implementation Batches 

  

	6.6.1	After the FEASIBILITY STUDY and the performance of the CONFIRMATORY BATCHES, BI Austria shall produce two (2) ** working volume
IMPLEMENTATION BATCHES for DRUG SUBSTANCE, media fills and two (2) IMPLEMENTATION BATCHES for DRUG PRODUCT. Pursuant to the mutually agreed production requirements set forth in Exhibit 20 BI Austria shall establish a ** fermentation scale and for purification a scale with a yield of ** grams DRUG SUBSTANCE per sublot. 

  

	6.6.2	The IMPLEMENTATION BATCHES shall be produced in the GMP production units at BI Austria to ensure the technical equipment is qualified with respect to the specific requirements for
the later GMP manufacture of DRUG PRODUCT. 

  

	6.6.3	BI Austria shall ferment and purify each IMPLEMENTATION BATCH in accordance with the process description which shall be established in a MASTER BATCH RECORD, to be drawn up by BI
Austria, reviewed by Corautus and released by BI Austria Quality Management. 

  

	6.6.4	BI Austria shall conduct in-process control testing on each manufacturing run and also conduct release testing of the IMPLEMENTATION BATCHES according to the DRUG PRODUCT
SPECIFICATIONS. Corautus will conduct any release testing for methods not transferred to BI Austria. 

  

	6.6.5	BI Austria shall warehouse DRUG PRODUCT produced in the IMPLEMENTATION BATCHES as requested by Corautus. Corautus shall decide on either disposing, or, provided the DRUG PRODUCT
meets SPECIFICATIONS, shipping such DRUG PRODUCT to Corautus. 

  

	6.6.6	As the DRUG PRODUCT from the IMPLEMENTATION BATCHES is of experimental nature and does not meet all GMP requirements, Corautus warrants that it shall not use such DRUG PRODUCT in
humans. 

  

	6.6.7	The PARTIES shall consider the yield and purity of the IMPLEMENTATION BATCHES and if the IMPLEMENTATION BATCHES do not meet the expected purity standards or expected yields based on
the DRUG PRODUCT SPECIFICATIONS the PARTIES will come to an agreement on further steps. In such events both PARTIES shall use commercially reasonable efforts to arrive at a mutually acceptable solution. For work packages in Exhibit 16 which are not
marked as “estimates” prices shall be final prices. However, if the scope of certain work packages is changed upon written agreement by both PARTIES prices shall be adjusted accordingly. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 20 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	6.7	Batches for Reference Standard and Clinical Trials 

  

	6.7.1	BI Austria shall manufacture such quantities of DRUG SUBSTANCE and DRUG PRODUCT for the reference standard and human clinical trials as set forth in the SERVICES in Exhibit 7 and in
accordance with the mutually agreed production requirements set forth in Exhibit 20. 

  

	6.7.2	As set forth in the project timelines in Exhibit 11, BI Austria shall manufacture, release, store and cause delivery of DRUG SUBSTANCE and DRUG PRODUCT for the reference standard
and human clinical trials in accordance with the TESTING SPECIFICATIONS and the MASTER BATCH RECORDS reviewed and approved by Corautus, the QUALITY AGREEMENT and GMP and all applicable laws, regulations and ordinances as required in the TERRITORY.

  

	6.7.3	Corautus shall conduct any release testing for methods not transferred to BI Austria as indicated in Exhibit 3 and 5. 

  

	6.8	Conformance Batches 

  

	6.8.1	BI Austria shall manufacture CONFORMANCE BATCHES which shall be at least three (3) consecutive BATCHES, in accordance with the timeline set forth in Exhibit 11 of this AGREEMENT and
subject to Section 6. 

  

	6.8.2	The CONFORMANCE BATCHES shall be manufactured at the same fermentation and purification scale as the batches for the reference standard and the clinical trials (see Section 6.7).

  

	6.8.3	The DRUG PRODUCT produced in the CONFORMANCE BATCHES is intended for clinical use and/or market supply by Corautus for use in humans. 

  

	6.8.4	BI Austria shall cause each CONFORMANCE BATCH to undergo in-process control testing, and release testing according to the DRUG PRODUCT SPECIFICATIONS using validated methods. BI
Austria shall manufacture, release, store and cause delivery of the CONFORMANCE BATCHES in accordance with the TESTING SPECIFICATIONS and the MASTER BATCH RECORDS reviewed and approved by Corautus, the QUALITY AGREEMENT and GMP and all applicable
laws, regulations and ordinances as required in the TERRITORY. 

  

	6.8.5	Corautus shall conduct any release testing for methods not transferred to BI Austria. 

  

	6.9	Labeling and Packaging 

  

	6.9.1	As requested by Corautus, BI Austria shall label and package clinical material in accordance with Corautus’ requirements and at Corautus’ costs and BI Austria shall charge
market prices therefor as customary in the biopharmaceutical industry. 

  

 Page 21 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	6.10	Stability Studies 

  
 BI Austria shall perform stability studies as set forth in Exhibit 26. 
  

	7.	TIMETABLE AND INCENTIVES 

  

	7.1	The PARTIES have agreed to a timeline for the SERVICES as set out in Exhibit 11. 

  

	7.2	The PARTIES will use commercially reasonable efforts to meet the expected timelines. However, if a PARTY becomes aware of circumstances which suggest that the estimated timelines in
Exhibit 11 will not be met, such PARTY shall notify the other PARTY within a reasonable period of time and the PARTIES will agree on further steps. In such events both PARTIES shall use commercially reasonable efforts to arrive at a mutually
acceptable solution. Adjustments of the timeline shall not adjust the pricing of the SERVICES under Exhibit 7 unless Corautus has requested or caused a delay of the commencement of the CONFORMANCE BATCHES as permitted under Section 6 hereof, and as
a result, the CONFORMANCE BATCHES are completed after **. The SERVICES attributable to the CONFORMANCE BATCHES which are performed after ** may have the price adjusted therefor in accordance with Section 17.2.1, subsection (i) and (ii) to reflect price increases from and after **. 

  

	7.3	Each PARTY acknowledges and agrees that it shall perform in a timely manner all of its obligations in this AGREEMENT. 

  

	7.4	As an incentive to BI Austria, in the event BI Austria timely and fully completes all of its obligations and delivers the DRUG SUBSTANCE and DRUG PRODUCT required under Section
6.7.1 and 6.7.2 on or before **, then Corautus shall pay a bonus to BI Austria of United States dollars ** within thirty (30) days of such date. If BI Austria fails to timely and fully complete all of its obligations and does not deliver DRUG
SUBSTANCE and DRUG PRODUCT required under Section 6.7.1 and 6.7.2 on or before March 17,2006, then BI Austria shall credit United States dollars ** to Corautus. 

  

	8.	DELAYED APPROVAL OF CLINICAL TRIALS 

  

	8.1.	Corautus shall promptly notify BI Austria in the event that one (1) and/or several approval processes of regulatory authorities for the DRUG PRODUCT is/are unexpectedly delayed and
such delays may have an impact on the SERVICES performed by BI Austria and the manufacturing timelines. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 22 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	8.2.	In such event, the co-operation between the PARTIES on DRUG PRODUCT is continued, and if the Rolling Forecast Model is already in effect, Corautus’ obligations for any PURCHASE
ORDER for the red zone of the Rolling Forecast (Section 10.4) remain unchanged; whereas for the blue zone of the Rolling Forecast Model Corautus can alter its forecast by ** percent but ** in each one of the four (4) respective quarters.

  

	9.	STERILITY DRUG SUBSTANCE 

  
 In the event sterility of DRUG SUBSTANCE is requested by the HEALTH AUTHORITIES BI Austria shall perform the required work to verify and validate
sterility of the DRUG SUBSTANCE filling process as set forth in Exhibit 27. 
  

	10.	CLINICAL AND COMMERCIAL MANUFACTURE DURING PERIOD THREE 

  

	10.1.	Product Supply 

  

	10.1.1	BI Austria covenants that all DRUG PRODUCT manufactured by BI Austria during PERIOD THREE and supplied to Corautus, or to Corautus’ representatives or AGENTS, for clinical use
or for market supply, shall be manufactured, released, stored and delivered to the carrier designated by Corautus in accordance with the SPECIFICATIONS (in particular, the DRUG PRODUCT SPECIFICATIONS and the MASTER BATCH RECORDS), QUALITY AGREEMENT
and GMP and all applicable laws, regulations and ordinances as required in the TERRITORY. 

  

	10.1.2	BI Austria warrants that all DRUG PRODUCT manufactured by BI Austria during PERIOD THREE for clinical use or market supply meets the DRUG PRODUCT SPECIFICATIONS.

  

	10.1.3	Details of the MANUFACTURER RELEASE, Quality Assurance (also called Quality Management), Quality Control, Validation, Inspections, Audits and other Regulatory requirements are
detailed in the QUALITY AGREEMENT, and Corautus and BI Austria each agree to comply with its obligations under the QUALITY AGREEMENT. 

  

	10.2.	Preliminary Market Launch Date and Product Estimate 

  

	10.2.1	Corautus expects to file the BLA for DRUG PRODUCT in the United States **. First launch of DRUG PRODUCT in the United States market is expected **. These dates are projections only, are non-binding and are subject to change. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 23 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	10.2.2	Corautus preliminary, non-binding forecast for the first three (3) years after market launch is given in Exhibit 17. 

  

	10.2.3	For early market supply (meaning the first two years after DRUG SUBSTANCE from the CONFORMANCE BATCHES has been used up) DRUG SUBSTANCE shall be manufactured at the same scale as
the CONFORMANCE BATCHES (see section 6.8.2); nothing in this sentence shall limit either PARTY’s obligations set forth in Sections 10.3. and 10.4. 

  

	10.3.	Minimum and Maximum Volume 

  

	10.3.1	Corautus shall inform BI Austria on the minimum and maximum volume of the amount of DRUG PRODUCT, in conformity with Corautus’ market projections, for which BI Austria is
obliged to reserve manufacturing capacity. 

  
 As
of the EFFECTIVE DATE (but subject to Section 10.3.4) the minimum and maximum volume per calendar year are: 
  

			
	 Minimum volume
	 	** DRUG SUBSTANCE
	 Maximum volume
	 	** DRUG SUBSTANCE

  

	10.3.2	Corautus may from time to time by written notice to BI Austria modify its minimum and maximum volumes, such revised minimums and maximums to take effect on the date specified in
such notice, but no sooner than two (2) years from the date of such notice. However, the minimum volume to be purchased shall never be less than such amount of DRUG PRODUCT per applicable calendar year as set forth in Section 10.3.4 which
incorporates at least ** of DRUG SUBSTANCE. As soon as the dose of DRUG SUBSTANCE per vial of DRUG PRODUCT is established for commercial supply, the PARTIES agree that the minimum and maximum volumes as set forth in this Section 10.3 shall be
restated in vials of DRUG PRODUCT instead of grams of DRUG SUBSTANCE. However, such determination shall, with regard to the quantities of DRUG SUBSTANCE, neither alter Corautus’ purchase obligations under this Section 10.3. nor BI
Austria’s obligation to reserve manufacturing capacity pursuant to Section 10.3.1. 

  

	10.3.3	The PARTIES agree that the ratio of the minimum volume to the maximum volume shall be **. The maximum volume however, shall not exceed ** DRUG SUBSTANCE unless agreed to by BI Austria in writing. Once sufficient demand for DRUG SUBSTANCE is established in PERIOD THREE and depending on
Corautus’ DRUG SUBSTANCE requirements, the PARTIES shall negotiate in good faith the procedure and costs for an upscale of the manufacturing process for DRUG SUBSTANCE and DRUG PRODUCT. 

  

	10.3.4	Commencing in the calendar year for which the red zone of the Rolling Forecast Model under Section 10.4 is first effective and binding, Corautus shall be obligated to purchase in
any year during the Term of this AGREEMENT at least the then current minimum volume for such year established under this Section 10.3. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 24 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	10.4.	Rolling Forecast 

  

	10.4.1	In order to try to plan future DRUG PRODUCT requirements for clinical and/or commercial supply during PERIOD THREE, Corautus shall provide three-year rolling forecasts with fixed
and variable quantities and timelines. The first three-year Rolling Forecast shall be provided by Corautus no later than two years before the first delivery date requested by Corautus of DRUG PRODUCT in PERIOD THREE.. 

  

	10.4.2	The details and timeline for the commercial manufacture of DRUG PRODUCT shall be done in accordance with the Rolling Forecast Model, which is attached to this AGREEMENT as Exhibit
18. 

  

	10.4.3	After the first forecast has been submitted by Corautus to BI Austria, successive forecasts shall be submitted on a quarterly basis at the latest on every first day of every new
calendar quarter. 

  

	10.5.	Packaging/Labeling by BI Austria 

  
 As requested by Corautus, BI Austria shall package and label the DRUG PRODUCT during PERIOD THREE in accordance with the applicable MASTER BATCH RECORD
and GMP at Corautus costs and BI Austria shall charge market prices as customary in the biopharmaceutical industry. 
  

	10.6.	Warehousing at BI Austria Facilities 

  

	10.6.1	BI Austria shall warehouse DRUG PRODUCT produced under GMP during PERIOD THREE. BI Austria shall warehouse DRUG PRODUCT free of charge up to the DATE AVAILABLE FOR DELIVERY plus a
further ** months. 

  
 Upon expiry of the
aforementioned ** month period BI Austria shall warehouse DRUG PRODUCT under GMP conditions at Corautus’ cost. BI Austria shall charge warehousing costs as customary in the biopharmaceutical industry. 

 

	10.6.2	DRUG PRODUCT not subject to FINAL RELEASE by Corautus shall be properly quarantined by BI Austria from DRUG PRODUCT which has undergone FINAL RELEASE. 

  

	10.6.3	During PERIOD THREE, Corautus shall specify the DATE(S) AVAILABLE FOR DELIVERY on the PURCHASE ORDER for DRUG PRODUCT. BI Austria shall review and approve any such PURCHASE ORDER
within four (4) weeks of receipt. BI Austria is obligated to accept all PURCHASE ORDERS that are consistent with the terms of this AGREEMENT. BI Austria shall deliver on a timely basis the released DRUG PRODUCT in accordance with the PURCHASE ORDER
and this AGREEMENT. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 25 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	10.6.4	Corautus shall be obligated to buy and BI Austria shall be obligated to manufacture only the quantities of DRUG PRODUCT which are subject of a PURCHASE ORDER.

  

	10.6.5	On or before the DATE AVAILABLE FOR DELIVERY, BI Austria shall approve the BATCH RECORDS, investigate all deviations, perform the MANUFACTURER RELEASE and supply Corautus with
documentation pursuant to Sections 11.3 for Corautus documentation review and batch FINAL RELEASE. 

  

	10.7.	Release 

  

	10.7.1	BI Austria shall be responsible for the MANUFACTURER RELEASE which shall be completed no later than ninety (90) calendar days from the Manufacturing Date of a batch.

  

	10.7.2	Corautus is responsible for the FINAL RELEASE of DRUG PRODUCT which shall be performed no later than sixty (60) calendar days from the MANUFACTURER RELEASE.

  

	10.7.3	BI Austria and Corautus shall establish an acceptable GMP procedure for BATCH RECORD review in accordance with Section 12.2. Original BATCH RECORDS will be completed and available
for review on site at BI Austria by Corautus upon request after MANUFACTURER RELEASE of each clinical and/or commercial BATCH. The review and approval of BATCH RECORDS is detailed in the QUALITY AGREEMENT. 

  

	10.7.4	BI Austria will undertake all warehousing and distribution activities in accordance with GMP and the applicable SPECIFICATIONS, as detailed in the QUALITY AGREEMENT.

  

	11.	SHIPMENT OF DRUG PRODUCT 

  

	11.1	All DRUG PRODUCT (and any samples thereof) shall be shipped to Corautus according to the Incoterm 2000 EXW (“ex works”) BI Austria’s facility.

  

	11.2	Corautus shall be responsible for obtaining any import license or other official authorization and carrying out any other customs formalities necessary for importation of the DRUG
PRODUCT, and for paying for all customs formalities as well as duties, taxes, and other official charges payable upon importation. 

  

	11.3	Drug Product Delivery and Delivery Documents 

  

	11.3.1	For DRUG PRODUCT manufactured and shipped during PERIOD TWO AND PERIOD THREE, BI Austria shall submit an invoice together with a packing list and a certificate of analysis
(“COA”). For DRUG PRODUCT manufactured under GMP BI Austria shall also issue and submit a certificate of compliance (“COC”). 

  

	11.3.2	The invoice shall state the quantity of DRUG PRODUCT in such shipment and the price therefore in accordance with Section 17.1.1 of this AGREEMENT. All invoices and other

  

 Page 26 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

 delivery documents shall be sent via fax to Corautus’ address for notices hereunder. Corautus
shall pay BI Austria for all invoiced DRUG PRODUCT amounts in accordance with Section 17. 
  

	11.3.3	In the event that DRUG PRODUCT which has been ordered by Corautus pursuant to a PURCHASE ORDER is not shipped to Corautus within ninety (90) calendar days of FINAL RELEASE for
reasons attributable to Corautus (e.g. lack of shipping instructions, etc.) the risk of the deterioration or perishing of the DRUG PRODUCT for whatever reason passes to Corautus unless such deterioration or perishing was caused by a willful or
grossly negligent act or omission by BI Austria. However, BI Austria shall continue to warehouse DRUG PRODUCT in accordance with Section 10.6. BI Austria shall render invoice and Corautus shall pay for such DRUG PRODUCT when the invoice becomes due.
BI Austria is entitled to claim reimbursement for storage costs incurred after expiry of the ninety (90) calendar day time limit. 

  

	11.4	Ownership and Insurance Liabilities 

  

	11.4.1	BI Austria shall retain title to the work-in progress and to any batch which has not yet been paid for in full by Corautus. However, this does not affect Corautus rights set forth
in Section 5.1.3, 20.1.2 and 20.2.1 of this AGREEMENT. Title to a batch shall pass to Corautus on payment in full to BI Austria for the batch. 

  

	11.4.2	Corautus shall obtain the appropriate insurance on the batch when the batch is shipped from BI Austria facilities. 

  

	11.4.3	BI Austria shall hold appropriate insurance for the work-in-progress and batches which are on site at BI Austria facilities. 

  

	12.	DOCUMENTATION 

  

	12.1	BI Austria will retain complete, accurate and authentic documents and records created by BI Austria for each batch, as required by GMP. 

  

	12.2	During the initial manufacture of GMP batches there will be a qualification period in which Corautus will undertake to qualify BI Austria as a manufacturer of DRUG PRODUCT
(“Qualification Period”). The PARTIES agree that during the Qualification Period BI Austria shall copy and send the full batch documentation for ** batches (i.e. the ** for Ph II, the ** for Ph III and the **
CONFORMANCE BATCHES) to Corautus. 

  

	12.3	The documents to be sent to Corautus during the Qualification Period and after the Qualification Period are set forth in the QUALITY AGREEMENT. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 27 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	12.4	Documents and records created by and for BI Austria shall be in German or English. The specific documents to be drafted in English or for which BI Austria will provide English
language translations all at the expense of BI Austria except as provided in Section 12.4.1 are listed in Exhibit 19. 

  

	12.4.1	The translation cost of that portion of Exhibit 19 which consists of Procedures of Analytical Methods (bullet 4 on Exhibit 19) shall be borne equally by the PARTIES, with the total
estimated cost of such translations not to exceed Euro 10.000. 

  

	12.4.2	Documents other than those listed in Exhibit 19 shall only be provided if agreed to by BI Austria. Translation costs shall be borne by Corautus. 

  

	12.5	In addition to the documents BI Austria shall provide under Section 12.3, BI Austria shall provide a trend analysis of the process which will include in-process data and results of
tests reported in the COA for the GMP batches. All data on the CONFORMANCE BATCHES will be provided in the respective validation documentation. During PERIOD THREE the trend analysis shall be provided in the Annual Product Review, as such term is
defined in the Quality AGREEMENT. 

  

	12.6	All documentation shall be available on-site at the BI Austria facilities for Corautus’ review. 

  

	13.	QUALITY CONTROL AND QUALITY MANAGEMENT 

  

	13.1	Validation Services 

  

	13.1.1	Validation Master Plan 

  
 The PARTIES shall agree on a VALIDATION master plan which shall establish the priorities and timetable for validating all critical systems, processes,
tests and equipment, among other things. Consideration shall be given to whether currently validated systems, processes and tests need to be re-validated by BI Austria. Based on the VALIDATION master plan, individual VALIDATION protocols shall be
created. 
  

	13.1.2	Facility, Equipment and Utility Qualification 

  
 BI Austria shall validate the systems, if not currently validated, relevant for the manufacture of DRUG PRODUCT. VALIDATION of critical systems not
already validated will be done in accordance with specified individual validation protocols, to be approved by BI Austria Quality Management. 
  

 Page 28 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	13.1.3	Process 

  
 BI Austria shall validate processes critical to the manufacturing of DRUG PRODUCT including operation of sterilizers, bioreactor controls, chromatography processes, filtration equipment and cleaning. VALIDATION of the
processes will be done in accordance with specified individual validation protocols to be approved of by BI Austria Quality Management. Corautus shall have the right to review and approve all product-specific VALIDATION protocols and final reports.
The timelines for such review and approval shall be agreed upon by the Project Teams of the PARTIES. 
  

	13.1.4	Test Methods 

  
 BI Austria shall validate those test methods which control critical characteristics or processes in the manufacture of DRUG PRODUCT, including, without
limitation, yield, purity and bioburden. Corautus shall have the right to review and approve all product-specific test method VALIDATION protocols and final reports. The timelines for such review and approval shall be agreed upon by the Project
Teams of the PARTIES. 
  

	13.2	Quality Control 

  

	13.2.1	BI Austria shall maintain a separate Quality Control unit which shall operate separately from the production staff for ensuring Quality Control in the manufacture of DRUG PRODUCT.

  

	13.2.2	The Quality Control unit at BI Austria will conduct the testing of raw materials, resins and consumables, packaging components, in-process products, and DRUG PRODUCT.

  

	13.3	Quality Management 

  

	13.3.1	BI Austria shall maintain a Quality Management unit, which will be separate from the Quality Control unit and production staff. The responsibilities of the Quality Management unit
are detailed in the QUALITY AGREEMENT. 

  

	13.3.2	BI Austria’s Quality Management unit shall review and approve all BATCH RECORDS and shall investigate all deviations on such BATCH RECORDS on a timely basis, but in any event
within ninety (90) calendar days from the Manufacturing Date of a BATCH. BI Austria shall follow-up with corrective and preventive actions, as required. 

  

	13.3.3	BI Austria’s Quality Management unit shall also ensure that BI Austria’s facilities and manufacturing operations for DRUG PRODUCT are in compliance with the
SPECIFICATIONS, GMP, BI Austria’s SOPs and with any other applicable law or regulation governing a contract manufacturer of biopharmaceuticals domiciled in Austria and in effect during the time of manufacture of DRUG PRODUCT.

  

	13.3.4	The Quality Management unit at BI Austria shall maintain appropriate SOPs, review and approve VALIDATION protocols, review proposed process changes and determine whether
re-validation is required, approve all procedures or applicable SPECIFICATIONS, particularly those effecting identity, quality and purity of DRUG PRODUCT. 

  

 Page 29 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	13.3.5	The BI Austria Quality Management unit shall ensure that changes in packaging, equipment, processes, warehousing and distribution that could affect DRUG PRODUCT effectiveness or
DRUG PRODUCT characteristics are re-validated. 

  

	13.4	Change Control 

  
 BI Austria shall inform Corautus of changes to DRUG PRODUCT-specific master manufacturing and testing documentation. Corautus shall review and approve
such changes prior to implementation. The details on Change Control are specified in the QUALITY AGREEMENT. 
  

	14.	REGULATORY 

  

	14.1	Regulatory Compliance 

  

	14.1.1	BI Austria and Corautus shall exercise all reasonable skill, care and diligence customary in the industry in the performance of their duties under this AGREEMENT and in accordance
with all applicable GMP-requirements. 

  

	14.1.2	BI Austria shall obtain and maintain all permits required under Austrian legislation in order to manufacture DRUG PRODUCT. BI Austria shall file and maintain for its facility in
Austria a Site Master File and a Drug Master File which will be provided or made available to the HEALTH AUTHORITIES whenever requested. 

  

	14.1.3	BI Austria shall notify Corautus within seven (7) days of receipt of any communication with any HEALTH AUTHORITY concerning the manufacture of DRUG PRODUCT and shall co-operate with
Corautus in the scheduling of any planned inspection concerning the manufacture of DRUG PRODUCT. 

  

	14.1.4	In the event BI Austria receives a Form 483 notice from the FDA or any equivalent European notice with respect to its facilities, its manufacturing processes, its Quality Control
and Quality Management or the SOPs concerning or impacting DRUG PRODUCT, it shall advise Corautus within thirty (30) calendar days of receipt of such notice. 

  

	14.2	Manufacturing Audits and Regulatory Inspections 

  

	14.2.1	Corautus rights and obligations with regard to audits and regulatory inspections are set forth in the QUALITY AGREEMENT. 

  

 Page 30 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	14.2.2	BI Austria shall take immediate steps to address and correct any/all concerns raised by a HEALTH AUTHORITY, including, without limitation, fully cooperating with Corautus in
securing FDA acceptance of BI Austria as the manufacturer of the DRUG PRODUCT and will correct any deficiencies or perform any modifications that prevent it from being so accepted as follows: 

  
 (i) Issues which are raised as a result of a regulatory inspection and which
are quality system violations or deficiencies or facility deficiencies which do not solely and specifically relate to DRUG PRODUCT shall be timely corrected at BI Austria’s costs. 
  
 (ii) With regard to any other modifications required by any HEALTH AUTHORITY which are related to the manufacturing process
of DRUG PRODUCT, the parties shall seek a mutually convenient solution as to the sharing of costs for such modifications. 
  
 (iii) If the PARTIES do not reach an agreement in writing on the sharing of costs within ninety (90) days of the notification by the HEALTH AUTHORITY of
the changes required pursuant to subsection (ii) of this Section or if BI Austria fails to comply with its obligations under subsection (i) of this Section, Corautus may, but is not obligated to, terminate this AGREEMENT pursuant to Section 27.2.2.

  

	14.3	Regulatory Filings 

  

	14.3.1	The PARTIES will mutually agree as to each PARTY’s responsibilities in ensuring the requisite information required for the regulatory filings is available and submitted. The
PARTIES shall work together to ensure all necessary and sufficient information and data for the Chemistry Manufacturing and Control (“CMC”) section of any regulatory filing is completed as required and which shall include BI Austria’s
participation in the writing of, and approval of, the sections of the CMC sections directed to the DRUG PRODUCT as produced by BI Austria. Any CMC section shall be written in English. BI Austria shall cooperate with Corautus at Corautus’
expense to fulfill its obligations necessary for such regulatory filings. 

  

	14.3.2	Corautus shall submit any regulatory correspondence, submissions or updates thereof by Corautus with any regulatory authority concerning DRUG PRODUCT or manufacture of DRUG PRODUCT
at the BI Austria facilities for review and approval in writing by BI Austria prior to making them available to such regulatory authority. The timelines for BI Austria’s review and approval of such documents shall not exceed thirty (30) days
unless otherwise agreed between the PARTIES. 

  

	15.	CORAUTUS’ ACCESS TO BI AUSTRIA FACILITIES 

  

	15.1	Corautus shall have the right to have technical personnel, namely two (2) employees, present in the production facilities during GMP manufacturing campaigns of DRUG PRODUCT.

  

 Page 31 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	15.2	Corautus personnel may be in attendance during clinical and/or commercial manufacture of DRUG PRODUCT during a scheduled audit or at request by BI Austria. 

 

	15.3	BI Austria shall accommodate Corautus personnel during such visits by providing an office area with access to photocopiers, telephone (voice and data) and facsimile.

  

	16.	DISPUTE RESOLUTION FOR NON-CONFORMING DRUG PRODUCT 

  

	16.1	Rejection Procedure / Confirmatory Third PARTY Testing 

  

	16.1.1	Within forty-five (45) calendar days of receipt of any DRUG PRODUCT during PERIOD TWO or PERIOD THREE at such destination as may be designated by Corautus, Corautus may perform such
sampling and tests to determine whether the DRUG PRODUCT meets the applicable DRUG PRODUCT SPECIFICATIONS, GMP and the other requirements of this AGREEMENT. If Corautus rejects any DRUG PRODUCT in accordance with this Section 16.1.1, Corautus shall
within such forty-five (45) working days of receipt of such DRUG PRODUCT inform BI Austria of its rejection of the batches of DRUG PRODUCT and the reasons therefor. 

  

	16.1.2	If Corautus does not so notify BI Austria, Corautus shall be deemed to have accepted the batches. 

  

	16.1.3	If the PARTIES disagree as to whether or not the said quantity of DRUG PRODUCT is non-conforming, then BI Austria shall re-test the respective retain samples, and other samples as
agreed between the PARTIES. 

  

	16.1.4	If the PARTIES continue to disagree as to whether or not the said quantity of DRUG PRODUCT meets DRUG PRODUCT SPECIFICATIONS, or is GMP grade, and suitable for FINAL RELEASE, then
such disagreement shall be submitted to the Steering Committee (see Section 18.8) for dispute resolution. 

  

	16.1.5	If the Steering Committee can not resolve such disagreement, a qualified independent party, acceptable to both PARTIES, will determine from a scientific perspective if the DRUG
PRODUCT meets DRUG PRODUCT SPECIFICATIONS, is GMP grade and suitable for FINAL RELEASE. The resulting scientific determination will be final and binding on BI Austria and Corautus. BI Austria will bear all cost of the third party evaluation if the
testing demonstrates that the DRUG PRODUCT is non-conforming. If the DRUG PRODUCT is determined to be conforming, then Corautus shall bear all costs of the third party evaluation. 

  

 Page 32 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	16.2	Replacement 

  

	16.2.1	If, during PERIOD TWO or PERIOD THREE, any DRUG PRODUCT is confirmed to be non-conforming in accordance with Section 16.1.5, BI Austria will promptly or, if the DRUG PRODUCT needs
to be remanufactured, no longer than within six (6) months after Corautus’ or any consignee’s receipt of such non-conforming DRUG PRODUCT, at Corautus’ option either replace such non-conforming DRUG PRODUCT or credit Corautus for such
DRUG PRODUCT if already paid for by Corautus, provided, that BI Austria is notified promptly in writing (including a reasonable description of the alleged non-conformance) upon discovery of any non-conformance of the DRUG PRODUCT. Other than
replacement of non-conforming DRUG PRODUCT and associated shipping and restocking charges and as otherwise provided in Section 23.2, subsection (b) and (c), BI Austria shall not be liable for any further claims by Corautus resulting from such
delivery of non-conforming DRUG PRODUCT. Section 23.5 applies to any liability of BI Austria under this Section 16.2. 

  

	16.2.2	If in the good faith judgment of Corautus, it is necessary or appropriate to withdraw or recall DRUG PRODUCT or issue an advisory letter regarding the DRUG PRODUCT, then Corautus
may undertake such withdrawal, recall or issue such advisory letter after consultation with BI Austria. Any withdrawal or recall of DRUG PRODUCT shall be in the sole discretion of Corautus. BI Austria will cooperate fully with Corautus in the event
of any recall or withdrawal and will provide at Corautus’ expense, such assistance in connection therewith as Corautus may reasonably request. 

  

	16.2.3	Any confirmed non-conforming PRODUCT shall at the option of BI Austria either be returned to BI Austria’s facilities or destroyed in either case at BI Austria’s costs.

  

	16.2.4	Any DRUG PRODUCT delivered by BI Austria as replacement of non-conforming DRUG PRODUCT shall be manufactured, tested, released, stored and delivered in accordance with the TESTING
SPECIFICATIONS and the MASTER BATCH RECORDS reviewed and approved by Corautus, the QUALITY AGREEMENT, GMP and all applicable laws, regulations and ordinances as required in the TERRITORY. 

  

	16.3	Stock Build-up 

  

	16.3.1	Both PARTIES shall stock reasonable quantities of DRUG PRODUCT in order to cope with potential temporary inabilities to supply. Such obligation shall become effective one year from
the first approval of DRUG PRODUCT. 

  

	16.4	Unforeseeable Quality Problems 

  

	16.4.1	In case BI Austria’s failure to deliver DRUG PRODUCT is due to quality problems that were unforeseeable for BI Austria and were not caused by any negligent act or omission by
BI Austria, then BI Austria shall perform an investigation to determine the cause for such quality problems which shall be completed within a maximum of four (4) months from notice of BI Austria’s Quality Management. 

 

 Page 33 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	16.4.2	On the basis of the outcome of this investigation the PARTIES shall decide on the further course of action with the involvement of the Steering Committee. The quantities of DRUG
PRODUCT ordered by Corautus shall either be taken, as far as possible, from stocks at BI Austria, Corautus or its licensee and/or shall be manufactured and delivered by BI Austria within further five (5) months following completion of the
investigation. In case BI Austria does not succeed in solving such quality problems within maximum nine (9) months from notice of BI Austria’s Quality Management, Corautus shall have the right to terminate the AGREEMENT.

  

	17.	PRICES AND PAYMENTS 

  

	17.1	Prices for the SERVICES 

  

	17.1.1	The prices for each work package of the SERVICES to establish the production process for DRUG PRODUCT in PERIOD ONE and PERIOD TWO shall be set forth in Exhibit 16. The prices for
DRUG PRODUCT-specific equipment (Section 4.1.) shall be paid according to the payment schedule set forth in Exhibit 16. In the event a task as set forth in Exhibit 7 is re-scheduled the PARTIES shall discuss and agree on an adjustment of the payment
schedule. Rescheduling of the CONFORMANCE BATCHES shall be subject to Section 6 and Section 7.2. Any work package shown in Exhibit 7 as an estimate is a good faith estimate of the cost for such work package. BI Austria and Corautus shall together
define the final scope of such work packages with the objective not to exceed the estimated prices. 

  

	17.1.2	The assumptions underlying the SERVICES to be performed by BI Austria and for the price calculation are defined in Exhibit 20. The price calculations, however, will not be adjusted
in the event the assumptions prove to be invalid, except for in the case of the invalidity of those assumptions listed on Exhibit 20 that are expressly shown thereon to effect pricing. 

  

	17.1.3	Any services requested by Corautus in writing, in excess of the SERVICES shall be remunerated additionally by Corautus. BI Austria and Corautus shall conduct good faith negotiations
as to the extent and price of such additional services. Prior to performing any services in excess of the SERVICES, BI Austria shall notify Corautus in writing that it considers such services to be excess. 

  

	17.2	Prices for DRUG PRODUCT during PERIOD THREE 

  

	17.2.1	During PERIOD THREE the prices for the DRUG SUBSTANCE and the DRUG PRODUCT for market supply and further clinical trials shall be fixed by the PARTIES in accordance with the price
formula given in Exhibit 24. Thereafter, the price will be adjusted on an annual basis pursuant to the following subsections. Prior to any adjustment notified by BI Austria, BI Austria shall provide to Corautus the basis for such adjustment as set
forth in subsections (i) and (ii) of this Section 17.2.1. together with such data as is reasonably necessary to confirm the 

  

 Page 34 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

 accuracy of the adjustment. The price adjustment shall be determined as of October 31 of each year
with effect for January 1 of the following year and shall be subject to the following principles, unless otherwise agreed by the PARTIES: 
  
 (i) Price Adjustment/Indexing. For the part of the purchase price for the DRUG PRODUCT which is based on the general costs of BI Austria (those
costs which are not specific for the DRUG PRODUCT), the adjustment will reflect the average of the figures of the annual percentage modification in the (a) National Consumer Price Index and (b) the Negotiated Standard Wage Rate Index, shown in the
statistic monthly report of the Oesterreichische Nationalbank (current: http://www.oenb.at). The basis for the calculation of the increase shall be the monthly report of the Oesterreichische Nationalbank for the month in which the price for the DRUG
PRODUCT has been fixed by the PARTIES for the first time. 
  
 (ii) Adjustment of Direct and Actual Costs. The purchase price will comprise an amount for direct and actual costs to BI Austria of (a) raw materials and consumables, (b) dedicated non capital-equipment and (c) services supplied to
BI Austria by third parties (“Third PARTY Materials and Services”) utilized in the manufacture of DRUG PRODUCT. If the accumulated direct and actual costs incurred by BI Austria deviate more than three percent (3%) from those indicated by
BI Austria when the purchase price was fixed, then the purchase price may be adjusted accordingly. In any event, BI Austria will provide to Corautus access to full and complete records of receipts or invoices paid by BI Austria resulting from the
purchase of Third PARTY Materials and Services used to manufacture the DRUG PRODUCT. Upon the written request of Corautus and at Corautus’ expense, an independent accountant acceptable to both PARTIES shall have access during normal business
hours to the actual receipts and invoices paid by BI Austria relating to the purchase of Third PARTY Materials and Services, as may be reasonably necessary to verify the accuracy of the payment records furnished by BI Austria. If such review of the
receipts and invoices shows a discrepancy between the amount BI Austria paid and the amount charged to Corautus, then the PARTIES will promptly meet and resolve such discrepancy. In any event, any overpayment by Corautus for direct and actual costs
to BI Austria shall be fully creditable against future amounts payable to BI Austria (or refunded to Corautus upon request by Corautus). 
  

	17.3	Taxes 

  

	17.3.1	The prices for the DRUG PRODUCT supplied by BI Austria under this AGREEMENT shall be exclusive of all export, import, sales, use or excise taxes, VAT, duties, tariffs, federal,
state or local tax, or any other taxes levied on the delivery of the DRUG PRODUCT pursuant to this AGREEMENT in the TERRITORY. Such taxes shall be borne by Corautus or the consignees designated by Corautus, respectively. 

  

	17.4	Currency 

  

	17.4.1	All payments to BI Austria by Corautus pursuant to this AGREEMENT shall be made in Euro and by wire transfer to the account(s) specified by BI Austria on the respective invoice.

  

 Page 35 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	17.5	Terms of Payment 

  

	17.5.1	All payments by Corautus to BI Austria shall be made within thirty (30) days of the submission of the appropriate original invoice by BI Austria detailing the matter to which the
invoice applies and the price in Euros. Invoices shall be sent via fax and by mail to Corautus’ address for notices hereunder. Payments made thirty (30) or more days after they are due shall bear interest at a rate of BI Austria’s current
applicable interest rate for a ninety (90)-day commercial loan from its current bank, or the maximum interest allowable under applicable law, if lower. 

  

	17.6	Accrual Accounting 

  

	17.6.1	For accounting purposes, BI Austria may render invoice on the 31st of December of each year for all SERVICES and performance (work in progress) rendered until such date even if the
entire work package to which such SERVICE and performance relates has not yet been completed. 

  

	18.	PROJECT MANAGEMENT, MEETINGS AND PLANNING 

  

	18.1	Each PARTY shall appoint a Project Manager for the course of the co-operation. All BI Austria and Corautus personnel involved in the manufacture of DRUG PRODUCT shall have the
appropriate credentials, experience and training to conduct the work required of them under this AGREEMENT. 

  

	18.2	The day-to-day operational implementation of the PARTIES’ obligations and issues which may arise with respect to the manufacture of DRUG PRODUCT under this AGREEMENT shall be
addressed by the Project Team as set forth in Exhibit 21. The Project Team shall be responsible for deciding operational and scientific issues. The Project Team must not make any decision which would result in an amendment of this AGREEMENT.

  

	18.3	The Project Team shall consist of a team consisting principally of equal numbers of BI Austria and Corautus people. Each PARTY will appoint its representatives. Each member of the
Project Team shall be a person of appropriate skill and experience. Either PARTY may change its own designated Project Team members. 

  

	18.4	There will be regularly scheduled telephone conferences and face-to-face meetings of the Project Team. These telephone conferences and meetings will include a report on progress
made, scheduled production, problems encountered and next stages. 

  

 Page 36 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	18.5	Decisions of the Project Team shall be reflected in the approved minutes prepared alternately by the PARTIES. Minutes of telephone conferences shall be drawn up within five (5)
business days and shall be deemed approved if they have not been objected to in writing by a PARTY within five (5) business days of receipt thereof and followed by issuance of two (2) copies of the minutes duly executed by the PARTIES’ Project
Managers. 

  

	18.6	Minutes of face-to-face meetings shall be drawn up within ten (10) business days and shall be deemed approved if they have not been objected to within ten (10) business days of
receipt thereof also followed by issuance of two (2) copies of the minutes duly signed by the PARTIES’ Project Managers. 

  

	18.7	In the event that the Project Team is unable to reach agreement on any issue and is unable to make decisions arising out of operational and scientific issues then the matter will be
referred to the Steering Committee for resolution. 

  

	18.8	The Steering Committee shall consist of the Project Manager of each PARTY and an equal number of representatives of each PARTY. Each PARTY shall appoint permanent representatives
from among its employees. It is the expectation of the PARTIES that appointees will change infrequently. The Steering Committee shall be responsible for unanimously agreeing in good faith on all issues on which the Project Team has been unable to
reach agreement on. The members of the Steering Committee are given in Exhibit 22. 

  

	18.9	The Steering Committee shall attempt in good faith to expeditiously and fairly resolve all issues before it. In the event that the Steering Committee is unable to resolve any issue
before it within three (3) weeks from the date that such issue is referred to it, such issue shall be referred to the Chief Executive Officer of BI Austria and the Chief Executive Officer of Corautus for prompt, good faith resolution. If such
individuals do not reach agreement on such issue within three (3) weeks of such referral, then each PARTY shall be free to pursue all available legal remedies. 

  

	19.	CONFIDENTIAL INFORMATION 

  

	19.1	A PARTY receiving CONFIDENTIAL INFORMATION from the other PARTY hereunder shall not disclose such information to any third party, except to those of its employees, directors and/or
officers who are bound by the terms of this AGREEMENT, who have a legitimate need to know such received Information for the Purpose of this AGREEMENT or for corporate reporting purposes and who are legally or contractually bound in writing to keep
such Information proprietary. For purposes of the foregoing, BI Austria may disclose such Information to employees, directors and/or officers of Boehringer Ingelheim GmbH, Ingelheim, Germany, and Boehringer Ingelheim Pharma GmbH & CoKG,
Ingelheim, Germany subject to the terms of this Section 19. Either party may disclose CONFIDENTIAL INFORMATION to such professional advisors who are bound by statutory confidentiality obligations (e.g., lawyers, tax consultants, accountants).
Disclosure to other third parties (e.g. 

  

 Page 37 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

 distributor, financial partners) shall only be permitted upon prior written consent of the other
PARTY and after conclusion of a separate non-disclosure agreement between the PARTIES and the relevant third party under confidentiality terms at least as stringent as those set forth herein. Furthermore, disclosure of CONFIDENTIAL INFORMATION shall
be permitted as set forth in Section 19.2. . 
  

	19.2	Each PARTY shall keep CONFIDENTIAL INFORMATION in strict confidence, use it solely for the purposes authorized herein and shall not disclose such information, except as set forth in
Section 19.1, for a period extending ten (10) years from the termination of all manufacturing of DRUG PRODUCT for Corautus by BI Austria according to this AGREEMENT, except as follows: 

  

	19.2.1	To the extent such information is or becomes general public knowledge through no fault of the recipient PARTY; or 

  

	19.2.2	To the extent such information can be shown by contemporaneous documentation of the recipient PARTY to have been in its possession prior to receipt thereof hereunder; or

  

	19.2.3	To the extent such information is, as shown by contemporaneous documentation of the recipient PARTY, received by the recipient PARTY lawfully from a third party lawfully in
possession of the CONFIDENTIAL INFORMATION; or 

  

	19.2.4	To the extent such information can be shown by contemporaneous documentation of the recipient PARTY to have been independently developed by the recipient PARTY; or

  

	19.2.5	Either PARTY may disclose to third parties or make public the INVENTIONS it owns pursuant to Section 20.2. 

  

	19.2.6	To the extent required by law, by local authorities for regulatory purposes or is necessary to perform its obligations under this AGREEMENT, in which case, the recipient PARTY may
disclose the information if the recipient PARTY gives the other PARTY prior notice of such disclosure and an opportunity to comment upon the content of the disclosure. 

  

	19.2.7	On or about 4 December 2003 the PARTIES entered into a Confidential Disclosure AGREEMENT (“CDA”) governing the disclosure and use of information concerning the matters
addressed in this AGREEMENT. The CDA is deemed cancelled as of the Effective Date of this AGREEMENT and all information exchanged under the CDA shall be subject to the confidentiality provisions of this AGREEMENT and shall be deemed to have been
exchanged after the EFFECTIVE DATE of this AGREEMENT. 

  

 Page 38 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	20.	INTELLECTUAL PROPERTY 

  

	20.1.	Ownership of INTELLECTUAL PROPERTY 

  

	20.1.1	BI Austria shall retain all ownership rights to INTELLECTUAL PROPERTY owned or controlled by BI Austria (“BI Austria INTELLECTUAL PROPERTY”) (a) prior to the EFFECTIVE
DATE, or (b) after the EFFECTIVE DATE excluding INVENTIONS. 

  

	20.1.2	Corautus shall retain all ownership rights to INTELLECTUAL PROPERTS owned or controlled by Corautus (“Corautus INTELLECTUAL PROPERTY”) (a) prior to the EFFECTIVE DATE, or
(b) after the EFFECTIVE DATE excluding INVENTIONS. 

  

	20.2.	Ownership of INVENTIONS 

  

	20.2.1	Any INVENTION which relates to the biological and pharmaceutical properties of DRUG PRODUCT or its progeny, any modifications thereto or the applications thereof and which is
generated during the term of this AGREEMENT shall be owned exclusively by Corautus (“Corautus INVENTION”). 

  

	20.2.2	Any INVENTION which relates to manufacturing, production processes and/or devices and which is generated during the term of this AGREEMENT shall be exclusively owned by BI Austria
(“BI Austria INVENTION”). 

  

	20.3.	License Grants 

  

	20.3.1	Corautus shall grant to BI Austria a non-exclusive, world-wide, royalty-free license for the term of this AGREEMENT to use such Corautus INTELLECTUAL PROPERTY and Corautus
INVENTIONS as necessary for the manufacture of DRUG PRODUCT for and only for Corautus. 

  

	21.	PROSECUTION 

  

	21.1.	Corautus shall be solely responsible for the filing, prosecution and maintenance of all INTELLECTUAL PROPERTY which is owned by Corautus. 

  

	21.2.	BI Austria shall be solely responsible for the filing, prosecution and maintenance of all INTELLECTUAL PROPERTY which is owned by BI Austria. 

  

 Page 39 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	22.	INFRINGEMENT OF PARTIES CONFIDENTIAL INFORMATION AND INTELLECTUAL PROPERTY 

  

	22.1.	Each PARTY shall promptly report in writing to the other PARTY during the term of this AGREEMENT any infringement, suspected infringement, unauthorized use or
misappropriation by a third party of any CONFIDENTIAL INFORMATION, INTELLECTUAL PROPERTY or INVENTION of which it becomes aware, and shall provide the other PARTY with all available evidence supporting said infringement, suspected infringement or
unauthorized use or misappropriation. 

  

	22.2.	Either PARTY may decide at its own discretion whether it is appropriate to initiate an infringement or other appropriate suit against any such third party

  

	22.3.	The PARTIES shall keep each other promptly informed about the status of any infringement or suit relating to such infringement, and shall mutually provide all reasonable
assistance in connection with such infringement or suit. 

  

	22.4.	The costs related to infringement or other suits shall be borne by the respective initiating PARTY. 

  

	22.5.	Any recovery of costs or damages which is received by either PARTY as a result of any legal action under this Section 22 shall be attributable to the respective PARTY. If
both PARTIES initiate such action, any recovery of costs or damages shall be attributable to both PARTIES according to their share of the costs of such action. 

  

	23.	INDEMNIFICATION AND LIABILITY 

  

	23.1	Indemnification of BI Austria by Corautus against third party claims 

  

Corautus shall indemnify and hold BI Austria and its AFFILIATES, and their respective directors, officers, employees and AGENTS harmless from and
against any and all third party claims, losses, damages, injuries, liabilities, court costs, fines, penalties and expenses (including, but not limited to, reasonable attorneys’ fees), arising out of, resulting from or caused by, or claimed to
arise out of, result from or be caused by 
  

	 	(a)	any marketing, distribution, sale or use of any DRUG PRODUCT supplied by BI Austria hereunder; or 

  

	 	(b)	any allegation by any third party of infringement of its intellectual property rights by Corautus or by any party from which Corautus is licensing INTELLECTUAL PROPERTY made
available to BI Austria under this AGREEMENT; or 

  

	 	(c)	any culpable breach by Corautus of any of its representations, warranties or covenants under this AGREEMENT; or 

  

 Page 40 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	 	(d)	any negligent or reckless activities or omissions, or willful misconduct of Corautus, its officers, employees or AGENTS 

  
 except to the extent such claims arise from the negligence, reckless
activities or omissions or willful misconduct of BI Austria. 
  

	23.2	Indemnification of Corautus by BI Austria against third party claims 

  

BI Austria shall indemnify and hold harmless Corautus, and its AFFILIATES, and their directors, officers, employees and AGENTS from and against any and
all third party claims, losses, damages, injuries, liabilities, court costs, fines, penalties and expenses (including, but not limited to, reasonable attorneys’ fees), arising out of, resulting from or caused by, or claimed to arise out of,
result from or be caused by BI Austria for any losses, claims, damages or liabilities arising from 
  

	 	(a)	any allegation by any third party of infringement by BI Austria of its intellectual property rights through the production of DRUG SUBSTANCE and/or DRUG PRODUCT; or

  

	 	(b)	any culpable breach by BI Austria of any of its representations, warranties or covenants under this AGREEMENT; or 

  

	 	(c)	any negligent or reckless activities or omissions, or willful misconduct of BI Austria, its officers, employees or AGENTS in the performance of its obligations under this AGREEMENT

  
 except to the extent such claims arise from the
negligence or reckless activities or omissions or willful misconduct of Corautus. 
  

	23.3	Notification of third party claims 

  
 If any claim is made for which a PARTY may seek indemnification from the other, the PARTY seeking indemnity (“Indemnitee”) shall promptly notify
the other PARTY (“Indemnitor”) of the nature and basis of such claims and amounts thereof, to the extent known. In the event any action, suit or proceeding is brought against a PARTY with respect to which the other PARTY will have full
liability hereunder, the other PARTY may, at its option and at its own expense, elect to assume the defense of any such action, suit or proceeding itself, and if it does not so elect, the PARTY having the action, suit or proceeding brought against
it will assume the defense thereof. If a PARTY may have only partial liability for any such action, suit or proceeding, the PARTIES will come to an agreement on how best to defend any such action, suit or proceeding. Neither PARTY shall make any
settlement of claims without the written consent of the other PARTY, which consent shall not be unreasonably withheld.  
  

 Page 41 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	23.4	Limitation of liability for third party claims 

  
 Each PARTY’s maximum aggregate liability to the other pursuant to Sections 23.1 and 23.2. shall in no event exceed ** Euros, except for gross
negligence and/or willful misconduct for which there is no maximum. 
  

	23.5	Liability for non-third party claims 

  
 The maximum aggregate liability of each PARTY to the other for all causes of action arising out of or related to this AGREEMENT, excluding liability under
Section 23.1 or Section 23.2. (for which the limitation of liability is set forth in Section 23.4), but including liability arising from a breach of this AGREEMENT or non-performance under this AGREEMENT shall not exceed the amounts paid or payable
by Corautus to BI Austria up to the point of notification, up to a maximum of **. This limitation of liability shall not apply in the event of breach or non-performance by willful act or omission. 
  
 Additionally, each PARTY shall be entitled to the recovery of reasonable
attorney’s fees from the other PARTY to the extent it prevails in arbitration or other proceedings pursuant to Section 30.3 of this AGREEMENT. 
  

	23.6	Disclaimer of consequential damages 

  
 Neither PARTY shall be liable to the other PARTY or its affiliates for any special, punitive, incidental, indirect or consequential losses or damages
(including loss of profits, business or goodwill) arising out of or relating to such PARTY’s or its affiliates performance or failure to perform its obligations hereunder, even if advised of the possibility of such damages, provided, however,
that nothing herein shall limit recovery by either PARTY for indemnification claims under Section 23.1 or 23.2 on the grounds that such indemnity claims are consequential damages.  
  

	23.7	Burden of proof 

  
 None of the provisions of this Section 23 shall change the statutory rules on the allocation of the burden of proof between the PARTIES.

  

	24.	INSURANCE 

  
 Each PARTY shall maintain adequate general liability and product liability insurance in such amounts and with such scope of coverage as is customary in
the biopharmaceutical industry with regard to manufacture, use and sale of a biopharmaceutical product . Either PARTY may any time after the EFFECTIVE DATE request the other PARTY to demonstrate the adequacy of the respective PARTY’s liability
insurance. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 42 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	25.	REPRESENTATIONS AND WARRANTIES 

  

	25.1.	Representations and Warranties by BI Austria 

  

	25.1.1	BI Austria is a corporation duly organized, validly existing and in good standing under the laws of the Federal Republic of Austria, and has full corporate power to conduct the
business in which it is presently engaged and to enter into and perform its obligations under this AGREEMENT. 

  

	25.1.2	BI Austria has taken all necessary corporate actions under the applicable laws and its articles of incorporation and bylaws to authorize the execution by its undersigned officers
and consummation of this AGREEMENT. 

  

	25.1.3	BI Austria maintains all necessary permits and authorizations as required under laws and regulations applicable to a contract manufacturing organization domiciled in Austria.

  

	25.1.4	The performance of the activities contemplated by this AGREEMENT will not conflict with any law or regulation applicable to BI Austria. 

  

	25.1.5	BI Austria is the rightful owner or licensee of any INTELLECTUAL PROPERTY that it may use in performing its obligations under this AGREEMENT and any INTELLECTUAL PROPERTY that it
owns or controls for performing its obligations under this AGREEMENT has no defects of title, nor has any claim of infringement been threatened or asserted, nor is such a claim pending. 

  

	25.1.6	BI Austria will obtain Corautus’ written approval in advance of any changes concerning or having impact on the DRUG PRODUCT and as further defined in the QUALITY AGREEMENT.

  

	25.1.7	Any DRUG PRODUCT delivered by BI Austria to Corautus designated carrier for shipment and which is designated for clinical use or market supply shall at the time of delivery to the
carrier conform to the SPECIFICATIONS and be manufactured, tested and stored in accordance with the SPECIFICATIONS and in accordance with GMP, and other applicable federal, state and local laws and regulations. 

  

	25.1.8	At the time of delivery to the carrier during PERIOD TWO or PERIOD THREE, the DRUG PRODUCT shall not as the result of BI Austria’s undertakings or BI Austria’s failure to
perform its undertakings as set forth in this AGREEMENT (i) be adulterated or misbranded within the meaning of Section 404 or 505 of the United States Food, Drug and Cosmetic Act, (“the Act”) as amended, and the regulations issued
thereunder or within the meaning of any applicable state or local law, the adulteration and misbranding provisions of which are similar to the Federal Act, or (ii) be prohibited from being introduced into interstate commerce.

  

 Page 43 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	25.2.	Representations and Warranties by Corautus 

  

	25.2.1	Corautus is a corporation duly organized, validly existing and in good standing under the laws of Delaware, and has full corporate power to conduct the business in which it is
presently engaged and to enter into and perform its obligations under this AGREEMENT. 

  

	25.2.2	Corautus has taken all necessary corporate action under the applicable laws and its articles of incorporation and bylaws to authorize the execution by its undersigned officers and
consummation of this AGREEMENT. 

  

	25.2.3	The performance of the activities contemplated by this AGREEMENT will not infringe upon the rights of any third party, nor conflict with any law or regulation applicable to
Corautus. 

  

	25.2.4	The INTELLECTUAL PROPERTY owned or controlled by Corautus and provided by Corautus to BI Austria under this AGREEMENT has no defects of title, nor has any claim of infringement been
threatened or asserted, nor is such a claim pending. 

  

	25.2.5	Corautus warrants that it will provide all relevant information in its possession regarding the MCB and the CORAUTUS WCB to BI Austria, and the fitness of such cells for use in a
multipurpose GMP production facility. Corautus further represents and warrants that such MCB and CORAUTUS WCB was prepared according to GMP and has previously been used in two multipurpose GMP facilities. 

  

	26.	TERM 

  
 The AGREEMENT shall commence on the EFFECTIVE DATE and shall continue in full force and effect for seven (7) years from grant of market authorization for a product containing the DRUG PRODUCT in the United States or
Europe (the “Initial Term”). Thereafter, the AGREEMENT shall be automatically renewed for successive four (4) year periods, unless either PARTY gives the other PARTY written notice of termination at least twenty-four (24) months prior to
the expiration of the Initial Term or any renewal period. 
  

 Page 44 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	27.	TERMINATION 

  

	27.1.	Termination by either PARTY 

  

	27.1.1	This AGREEMENT may be terminated by a PARTY, effective immediately upon written notice in the event: 

  

	 	(a)	The other PARTY has committed a material breach of the provisions of this AGREEMENT and such breach has not been cured within thirty (30) days (or such longer period provided below)
from receipt of written notice issued by the non-breaching PARTY to the breaching PARTY that specifies material breach and that further states that the non-breaching PARTY may terminate the AGREEMENT if such breach is not cured within the cure
period. The cure period for purposes hereof shall be thirty (30) days; provided, however, such cure period shall be extended if the identified breach is incapable of cure within thirty (30) days and if the breaching PARTY promptly commences efforts
to cure the breach and diligently prosecute such cure; or 

  

	 	(b)	the other PARTY becomes insolvent, makes a general assignment for the benefit of its creditors, files a petition in bankruptcy, has an involuntary petition of bankruptcy filed
against it and such petition is not dismissed within sixty (60) days, or has a receiver appointed for its property (“Insolvency”). 

  

	27.2	Termination by Corautus 

  

	27.2.1	Corautus may terminate this AGREEMENT if (a) Corautus’ development of the DRUG PRODUCT is placed on hold, suspended or stopped for scientific or medical reasons (including
failure to achieve satisfactory results in clinical trials) and Corautus gives up clinical development of the DRUG PRODUCT for all indications, or (b) if the DRUG PRODUCT fails to become licensed by the FDA on or before** or, having become licensed,
has such license suspended or revoked. In case of termination by Corautus for the reasons set forth in this Section 27.2.1 Corautus shall pay to BI Austria the sum of 

  
 (A) ** % of the price for the Task(s) (excluding Task 7) shown on Exhibit 16 which BI Austria has already performed and
those in which BI Austria is then engaged at the date notice is given of termination, less amounts paid on such Task(s), plus 
  
 (B) ** % of the price for the next succeeding Task (other than Task 7) or, if purchase orders have been submitted for DRUG PRODUCT, ** of the price of
such ordered DRUG PRODUCT, plus 
  
 (C) ** % of the scheduled
payments for Task 7 (stability studies) in the six (6) calendar months following the month in which the notice of termination was given; 
  
 provided that Tasks 6 and 6(a) may not be commenced prior to **; and provided further, the price of Task 6 and Task 6(a) shall not be included in the
above computation if on the date of termination Corautus still has the right to delay the commencement date of such Tasks under Section 6. 
  
 Model calculations are set forth in Exhibit 23 for explanatory purposes. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 45 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	27.2.2	Corautus may terminate this AGREEMENT (a) during PERIOD ONE if BI Austria, with or without fault, is unable to complete the Implementation Batches producing a yield and quality of
DRUG SUBSTANCE and DRUG PRODUCT that meets the standards set forth on Exhibit 3 and 5 of this AGREEMENT; (b) during PERIOD ONE, PERIOD TWO or PERIOD THREE as permitted in Section 14.2.2 or Section 16.4.2 or Section 32. 

  
 In the event of termination by Corautus under this Section 27.2.2, Corautus
shall pay to BI Austria **% of the cost of SERVICES already performed and intermediate products, DRUG SUBSTANCE and
DRUG PRODUCT manufactured in accordance with a PURCHASE ORDER through the date of termination to the extent not already paid. 
  

	27.2.3	In the case of termination by Corautus for the reason set forth in 27.1.1, BI Austria shall 

  

	 	(a)	transition all of its manufacturing activities of the DRUG PRODUCT to a competent replacement GMP manufacturer selected by Corautus, including the provision of copies of such master
documents and records required to enable such manufacturer to establish the manufacturing process; 

  

	 	(b)	deliver to Corautus the CORAUTUS WCB and the MCB, all materials supplied by Corautus to BI Austria and all work-in-progress of DRUG SUBSTANCE or of DRUG PRODUCT;

  

	 	(c)	grant Corautus a non-exclusive worldwide and royalty-free license to use and permit the manufacturer selected in accordance with subsection (a) of this Section to use any
INTELLECTUAL PROPERTY of BI Austria which is applied by BI Austria for the manufacture of DRUG PRODUCT. 

  

	27.3	Termination by BI Austria 

  

	27.3.1	Non-payment In the event Corautus fails to pay any amount due under this AGREEMENT within twenty (20) working days after receipt of the second written notice of such failure from BI
Austria, the PARTIES shall convene a meeting at a mutually convenient location between senior management to resolve such payment dispute. In the event senior management cannot resolve such dispute within thirty (30) days of such meeting, either
party may invoke the arbitration proceedings pursuant to Section 30 of this AGREEMENT. BI Austria shall have the right to suspend performance of the SERVICES or the manufacture of DRUG PRODUCT during such arbitration proceedings. Deviating from the
foregoing, BI Austria shall not suspend the performance of the SERVICES or manufacture of DRUG PRODUCT if Corautus pays the disputed amount to BI Austria no later than when the respondent under the arbitration proceedings is requested by the
arbitral tribunal to file its first answer to the claim. Any such payment shall be rendered by Corautus without prejudice. 

  

	27.3.2	In case of termination of this AGREEMENT by BI Austria in accordance with Section 27.1. or Section 27.3.1. or Section 35.2, Corautus shall pay to BI Austria the sum of

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 46 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	 	(a)	Termination during PERIOD ONE and PERIOD TWO:  

  
 (A) ** % of the price for the Task(s) (excluding Task 7) shown on Exhibit 16 which BI Austria has already performed and those in which BI Austria is then
engaged at the date notice is given of termination, less amounts paid on such Task(s), plus 
  
 (B) ** % of the price of the next succeeding Task (other than Task 7) scheduled and DRUG PRODUCT ordered in the next succeeding twenty-four (24) months following the date termination notice is given, plus 

 
 (C) ** % of the scheduled payments in Task 7 (stability studies) in the
six (6) months following the date notice is given of termination. 
  
 Model calculations are set forth in Exhibit 23 for explanatory purposes. 
  

	 	(b)	Termination during PERIOD THREE:  

  
 ** % of the purchase price of the DRUG PRODUCT requested by Corautus in the
Red and Blue Zone of the then current binding Rolling Forecast, plus ** % of the price of any ancillary services then requested by Corautus for the next succeeding ** months following the date termination notice is given, in each case to the extent
not already paid. 
  
 Model calculations are set forth in
Exhibit 23 for explanatory purposes. 
  

	28.	MITIGATION 

  

	28.1.	BI Austria will use reasonable commercial efforts to mitigate any payments by Corautus due upon termination. 

  

	28.2.	Corautus will use reasonable commercial efforts to mitigate any payments by BI Austria due upon termination. 

  
 29. EFFECT OF TERMINATION OR EXPIRATION 
  

	29.1.	Sections 20, 21, 22, 23, 24, 27, 28, 29, 30, 37 shall survive termination or expiration of this AGREEMENT (as the case may be) and shall remain in full force and effect.

  

	29.2.	The provisions of Section 19 shall survive termination or expiration of this AGREEMENT (as the case may be) and shall remain in full force and effect for ten (10) years after
termination or expiration of this AGREEMENT. 

  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 47 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	29.3.	The provisions of Section 4.2. shall survive termination or expiration of this AGREEMENT (as the case may be) and shall remain in full force and effect for two (2) years after
termination or expiration of this AGREEMENT. 

  

	29.4.	Termination of this AGREEMENT shall not release any PARTY from any liability for payment accrued or accruing to the other PARTY prior to the termination date.

  

	29.5.	In the event of expiration, each PARTY shall promptly return to the other PARTY or destroy, at the election of the other PARTY, all of the other PARTY’s CONFIDENTIAL
INFORMATION. Each PARTY shall maintain copies of documentation or samples as required by that PARTY under GMP and may also keep one copy or sample for legal archival purposes only. This obligation does not extend to any regulatory filings including
CONFIDENTIAL INFORMATION; such filings may only be used further for regulatory purposes. 

  

	29.6.	Upon termination of this AGREEMENT for any reason and provided BI Austria receives all payments due by Corautus, BI Austria shall (i) make available all DRUG PRODUCT-specific
equipment paid for by Corautus in accordance with Sections 4.1 and 4.1.1 and (ii) deliver all materials, including but not limited to samples, DRUG SUBSTANCE, DRUG PRODUCT, and intermediate products. 

  

	30.	GOVERNING LAW AND ARBITRATION 

  

	30.1.	This AGREEMENT shall be governed, construed and interpreted by the laws of Austria without reference to the conflict of laws provisions thereof. The application of the Convention on
the International Sale of Goods (CISG) is expressly excluded. 

  

	30.2.	The PARTIES hereto agree to consult with each other and to use their best efforts to resolve any dispute amicably. 

  

	30.3.	If the PARTIES are unable to resolve any dispute arising under this AGREEMENT, a PARTY who desires to submit a dispute to arbitration shall deliver notice to that effect to the
other PARTY. The PARTIES agree that all disputes between them arising out of or in connection with this AGREEMENT shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce (“ICC”) by one or three
arbitrators appointed in accordance with the said rules. The place for arbitration shall be Zurich, Switzerland, and the proceedings shall be conducted in English language. In such arbitration, the arbitrator(s) shall apply the substantive laws of
Austria. Unless otherwise designated by the arbitrator’s award, the PARTIES shall equally share the cost of the arbitrators. The award for arbitration shall be final and binding and may be enforced in any court of competent jurisdiction against
Corautus or BI Austria. Notwithstanding the foregoing but without abrogating the AGREEMENT of the PARTIES to binding arbitration, Corautus and BI Austria shall each be entitled either prior to or during arbitration to seek and obtain injunctive or
other equitable relief in any court of competent jurisdiction to preserve the status quo pending arbitration or to prevent the breach of this AGREEMENT. 

  

 Page 48 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	31.	WAIVER 

  

	31.1.	The failure by any PARTY at any time to enforce any of the terms or provisions or conditions herein or exercise any right hereunder shall not constitute a waiver of the same or
affect the validity of this AGREEMENT or any part hereof, or that PARTY’s rights thereafter to enforce or exercise the same. 

  

	32.	FORCE MAJEURE 

  
 A PARTY shall not be held liable to the other for any delay in performance, part performance, defective performance or non-performance of that PARTY which
is caused by or is a result of any circumstance beyond its reasonable control (force majeure). Without prejudice to the generality of the foregoing, industrial disputes, strike lockout, riots, mobs, fires, floods, or other natural disasters, civil
strife, embargo, lack or failure of transport facilities, currency restrictions, or events caused by reason of laws, regulations or orders by any government, governmental agency or instrumentality (which are not related to facts, events or
conditions that would also be a breach by such PARTY of its obligation under this AGREEMENT) shall be regarded as force majeure; provided, however, that the PARTY affected shall: give prompt written notice to the other PARTY of the date of
commencement of the force majeure, the nature thereof, and expected duration; and shall use its best efforts to avoid or remove the force majeure to the extent it is able to do so; and shall make up, continue on and complete performance when such
cause is removed to the extent it is able to do so. Either PARTY has the right to terminate this AGREEMENT with immediate effect, upon written notice to the other PARTY, should the force majeure continue for more than twelve (12) months following
the first notification. 
  

	33.	SEVERABILITY 

  
 In the event that any provision of this AGREEMENT is held by a court of competent jurisdiction to be unenforceable because it is invalid or in conflict
with any law or any relevant jurisdiction, the validity of the remaining provisions shall not be affected and the rights and obligations of the PARTIES shall be construed and enforced as if the AGREEMENT did not contain the particular provisions
held to be unenforceable. Such invalid or unenforceable provisions shall be substituted by valid regulations, which achieve to the greatest extent possible the economic, legal, and commercial objectives of the invalid or unenforceable provisions.

  

 Page 49 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	34.	NOTICES 

  
 All written communications, reports and notices between the PARTIES shall be in English and shall be delivered or sent by prepaid mail, registered mail
(return receipt requested), Federal Express or other recognized overnight courier, or facsimile transmission (facsimile confirmation to be produced upon request) to the attention of the PARTY at the addresses designated below, or any other addresses
of which either PARTY shall notify the other PARTY in writing. 
  
 Notices to BI Austria shall be to: 
  
 Boehringer
Ingelheim Austria GmbH 
 Dr. Boehringer-Gasse 5 – 11 
 A-1121 Vienna 
 AUSTRIA 
  
 Notices to Corautus shall be to: 
  
 Corautus Genetics Inc. 
 75 Fifth Street, NW, Suite 313 
 Atlanta, GA 30308 
 USA 
  

	35.	ASSIGNMENT AND ENUREMENT 

  

	35.1.	Either PARTY shall have the right to assign this AGREEMENT and the rights and obligations hereunder to any of its AFFILIATES or to any party that is successor to the business
interests of the assigning PARTY relating to the manufacturing of the Drug Product. 

  
 Each PARTY shall notify the other of any assignment without undue delay, in any event no later than concurrently with its first public announcement of
such assignment. 
  

	35.2.	Notwithstanding the PARTIES’ rights set forth in Section 35.1, Corautus may not assign this AGREEMENT and/or any rights and/or obligations hereunder AGREEMENT to a direct
competitor of BI Austria as named by BI Austria from time to time under Section 35.3. Any assignment in breach of the aforementioned sentence shall be null and void and entitles BI Austria to terminate this AGREEMENT with immediate effect. For
purposes of this Section 35.2 an “assignment of this AGREEMENT to a direct competitor of BI Austria” shall mean: (i) a consolidation, merger or similar transaction of Corautus with or into such direct competitor; or (ii) the sale, lease,
transfer, conveyance or other disposition (other than by way of merger or 

  
  

 Page 50 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

 consolidation), in one or a series of related transactions, of all or substantially all of the assets
of Corautus or of all or substantially all intellectual property rights of Corautus in VEGF-2 to a direct competitor; or (iii) any transaction that results in a representative of a direct competitor being on the Board of Directors of Corautus; or
(iv) any transaction or disposition to which Corautus is a party that results in a direct competitor being entitled to exercise rights of Corautus under this AGREEMENT or to substantially enjoy the benefits of such rights of Corautus
vis-à-vis BI Austria. 
  

	35.3.	Corautus may from time to time request in writing that BI Austria provide a list of its direct competitors. A direct competitor of BI Austria is any entity properly and timely
listed by BI Austria under the procedure set forth herein and which is a contract manufacturing organization with manufacturing capacities which are comparable or superior to BI Austria in the field of the manufacture of pharmaceutical compositions
via genetically modified microorganisms. Any entity not specifically named on the list, but which is directly or indirectly owned by a direct competitor listed by BI Austria, for the purpose of which “ownership” shall have the same meaning
as set forth in Section 1.1, shall also be deemed to be a direct competitor. Corautus may make such request at any time, but not more than four (4) times per calendar year (including, but not limited to, at times during which Corautus is considering
an assignment). BI Austria shall confirm receipt of such request and shall provide Corautus with a written list not to exceed ten (10) entities which are direct competitors of BI Austria and shall provide such list not later than fourteen (14)
calendar-days after request. Additionally, BI Austria may provide such list at any time in its own discretion to Corautus, but not more than four (4) times per year. Any list provided by BI Austria that has not been requested by Corautus shall not
be considered effective until seven (7) days after receipt by Corautus. Subject to the foregoing, each list provided by BI Austria shall supercede and replace all prior lists. Corautus may rely upon any list provided by BI Austria for a period of
six (6) months or until any new list is received from BI Austria by Corautus and becomes effective. Once Corautus makes a public announcement of an assignment or intended assignment, BI Austria may not name as a direct competitor any entity named by
Corautus in such announcement, and any list received by Corautus which contains the name of such entity which is not effective at the time of the announcement shall thereafter not become effective with regard to such entity. If Corautus announces an
assignment or intended assignment with an entity which does not become effective within twelve (12) months of the date of the announcement, then BI Austria may thereafter name the entity with whom Corautus had announced such assignment or intended
assignment on succeeding lists to be provided from BI Austria to Corautus under the terms hereof if such entity otherwise meets the definitions contained herein. 

  

	35.4.	This AGREEMENT shall be binding on all successors and permitted assignees. 

  

 Page 51 of 138 / Confidential 

 ABCD                         
  

Boehringer Ingelheim 
 Austria
GmbH               
  

	36.	INTEGRATION 

  
 This AGREEMENT represents the entire understanding of the PARTIES and supersedes all other agreements, expressed or implied, between the PARTIES
concerning the subject matter herein, except the Confidential Disclosure AGREEMENT dated 4 December 2003. 
  
 No waiver, alteration, or modification of any of the provisions of this AGREEMENT shall be binding unless made in writing and signed by the PARTIES’
respective officers thereto duly authorized. 
  

	37.	PUBLICITY 

  
 Each PARTY shall maintain the confidentiality of all provisions of this AGREEMENT, and, without the prior consent of the other PARTY, neither PARTY shall
make any press release or other public announcement of or otherwise disclose this AGREEMENT or any of its provisions to any third party, except for disclosures with the United States Securities and Exchange Commission and such disclosure as may be
required by applicable law or governmental regulation. In the event that either PARTY is required to file this AGREEMENT with the United States Securities and Exchange Commission, that PARTY shall seek PARTIES confidential treatment of sensitive
information of either PARTY (in particular, but not limited to trade secrets, confidential commercial or financial information) in this AGREEMENT. Prior to any submission, the PARTY required to make such submission shall inform the other party in
writing about the submission and the extent to which confidential treatment is sought in order to enable the other PARTY to comment on such submission. The PARTY required to make the submission shall use all reasonable efforts to incorporate such
comments. 
  
 IN WITNESS WHEREOF, the PARTIES hereto have caused this AGREEMENT to
be executed by their duly authorized representatives. 
  

							
	CORAUTUS GENETICS Inc.	 	 	 	BOEHRINGER INGELHEIM
	 	 	 	 	 	 	AUSTRIA GmbH
				
	By:	 	 /s/ Richard E. Otto

	 	By:	 	 /s/ Dr. Kurt Konopitzky

	 	 	Richard E. Otto	 	 	 	Dr. Kurt Konopitzky
	 	 	CEO & President	 	 	 	Head Div.Biophrmaceuticals/Operations
				
	Date:	 	 May 13, 2005

	 	Date:	 	 May 13, 2005

				
	 	 	 	 	By:	 	 /s/ Prof. Rolf G. Werner

	 	 	 	 	 	 	 
	 	 	 	 	 	 	Prof. Rolf G. Werner
	 	 	 	 	 	 	Head Corporate Division Biopharmaceuticals
				
	 	 	 	 	Date:	 	 May 13, 2005

	 	 	 	 	 	 	 

  

 Page 52 of 138 / Confidential 

 LIST OF EXHIBITS 
  

					
	 Exhibit 1:
	 	 CORAUTUS WCB
	 	54
	 Exhibit 2:
	 	 Description of DRUG SUBSTANCE
	 	55
	 Exhibit 3:
	 	 DRUG SUBSTANCE SPECIFICATIONS
	 	60
	 Exhibit 4:
	 	 Description of DRUG PRODUCT
	 	63
	 Exhibit 5:
	 	 DRUG PRODUCT SPECIFICATIONS
	 	64
	 Exhibit 6:
	 	 FEASIBILITY STUDY
	 	66
	 Exhibit 7:
	 	 BI Austria SERVICES
	 	69
	 Exhibit 8:
	 	 European Countries of the TERRITORY
	 	76
	 Exhibit 9:
	 	 BI Austria patent estate (patent applications) for BI Austria plasmid DNA manufacturing technology
	 	77
	 Exhibit 10:
	 	 Corautus Patents applicable to DRUG SUBSTANCE and DRUG PRODUCT
	 	78
	 Exhibit 11:
	 	 Project Timelines
	 	79
	 Exhibit 12:
	 	 Documents provided by Corautus
	 	80
	 Exhibit 13:
	 	 Materials provided by Corautus
	 	83
	 Exhibit 14:
	 	 Production areas for DRUG SUBSTANCE and DRUG PRODUCT
	 	84
	 Exhibit 15:
	 	 Documentation to be reviewed and approved by Corautus
	 	86
	 Exhibit 16:
	 	 Prices for the SERVICES and Payment Schedule
	 	87
	 Exhibit 17:
	 	 Corautus pre-liminary, non-binding Forecast –in Commercialization
	 	91
	 Exhibit 18:
	 	 Rolling Forecast Model
	 	92
	 Exhibit 19:
	 	 Documents to be provided by BI Austria in English
	 	95
	 Exhibit 20:
	 	 Mutually agreed Production Requirements
	 	97
	 Exhibit 21:
	 	 Project Team
	 	99
	 Exhibit 22:
	 	 Steering Committee
	 	100
	 Exhibit 23:
	 	 Termination Fee
	 	101
	 Exhibit 24:
	 	 Price formula for DRUG SUBSTANCE and DRUG PRODUCT manufactured in PERIOD THREE
	 	109
	 Exhibit 25:
	 	 Quality Agreement
	 	113
	 Exhibit 26:
	 	 Stability Studies
	 	116
	 Exhibit 27:
	 	 Sterility DRUG SUBSTANCE
	 	139

  

 Page 53 of 139 / CONFIDENTIAL 

 Exhibit 1: CORAUTUS WCB 
  

The WCB provided by Corautus (Lot No: 36732-2, for the provided amounts see Exhibit 13) was produced by Human Genome Sciences, Inc. in April 1999. A Certificate of
Analysis is available to BI Austria. The utilized strain is **. Each vial of the 400 vial-bank contains 1.2 mL cell suspension stored in soytone with 30 % glycerol in liquid nitrogen. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 54 of 139 / CONFIDENTIAL 

 Exhibit 2: Description of DRUG SUBSTANCE 
  

	2.1.	Origin and description of the host organism 

  
 ** 
  
 Figure 1. pVGI.1(VEGF2) Plasmid 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 55 of 139 / CONFIDENTIAL 

 ** 
  

	2.2.	Sequence of the plasmid 

  
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 56 of 139 / CONFIDENTIAL 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 57 of 139 / CONFIDENTIAL 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  
  

 Page 58 of 139 / CONFIDENTIAL 

	2.3.	Description of the DRUG SUBSTANCE and its biochemical properties 

  
 pVGI.1(VEGF2) DRUG SUBSTANCE is a clear, colorless, and particle free plasmid DNA solution. ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 59 of 139 / CONFIDENTIAL 

 Exhibit 3: DRUG SUBSTANCE SPECIFICATIONS 
  
 Implementation of Process into GMP Plant 
  
 Document A-1: Testing Requirement for the DRUG SUBSTANCE (1 mg/mL) from IMPLEMENTATION BATCHES 
  
 GMP Production for Phase II and III 
  
 Document B-1: DRUG SUBSTANCE SPECIFICATION (1 mg/mL) for release testing Document B-2: Diluted DRUG SUBSTANCE SPECIFICATION for release testing (133 μg/mL
& 33 μg/mL) before Filling 
  
 Conformance Batches & Validation

  
 Document B-1 
 Document B-2 
  
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 60 of 139 / CONFIDENTIAL 

 Document B-1: DRUG SUBSTANCE SPECIFICATION (1 mg/mL) for release testing 
  
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 61 of 139 / CONFIDENTIAL 

 Document B-2: Diluted* DRUG SUBSTANCE SPECIFICATION for release testing (133 μg/mL & 33 μg/mL) before
Filling 
  
 ** 
  

	*	Must be diluted with the released final formulation buffer. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 62 of 139 / CONFIDENTIAL 

 Exhibit 4: Description of DRUG PRODUCT 
  
 The drug product is an injectable form of plasmid DNA (pDNA) at 1 mg/mL or 0.133 mg/mL or 0.33 mg/mL, prepared from bulk pVGI.1 (VEGF2). **

  
 Formulation Buffer 
  
 ** 
  
 Formulation Buffer SPECIFICATIONS for IPC testing 
  
 ** 
  
 Placebo SPECIFICATIONS for release testing 
  
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 63 of 139 / CONFIDENTIAL 

 Exhibit 5: DRUG PRODUCT SPECIFICATIONS 
  
 Implementation of Process into GMP Plant 
  
 Document A-2: Testing Requirement for DRUG PRODUCT (1 mg/mL & 33 μg/mL) for IMPLEMENTATION BATCHES 
  
 GMP Production for Phase II and III 
  
 Document B-3: DRUG PRODUCT SPECIFICATION (1 mg/mL, 133 μg/mL & 33 μg/mL) for release testing 
  

	Conformance	Batches & Validation 

  
 Document B-3 
  
 A-2: Testing Requirement for DRUG PRODUCT (1 mg/mL, & 33 μg/mL) from IMPLEMENTATION BATCHES 
  
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 64 of 139 / CONFIDENTIAL 

 Document B-3: DRUG PRODUCT SPECIFICATION (** mg/mL, ** μg/mL & ** μg/mL) for release testing 

 
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 65 of 139 / CONFIDENTIAL 

 Exhibit 6: FEASIBILITY STUDY 
  
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 66 of 139 / CONFIDENTIAL 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 67 of 139 / CONFIDENTIAL 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 68 of 139 / CONFIDENTIAL 

 Exhibit 7: BI Austria SERVICES 
  

									
	#

	  	 Activities

	  	# of Runs

	 	Price [Euro]

	 	Estimate only

	1	  	 TASK 0 Feasibility Study
	  	 	 	 	 	 
	2	  	 **
	  	**	 	**	 	 
	3	  	 	  	**	 	**	 	 
	4	  	 	  	 	 	 	 	 
	5	  	 TASK 1: ** Confirmatory Runs*
	  	 	 	 	 	 
	6	  	 **
	  	 	 	**	 	 
	7	  	 **
	  	**	 	**	 	 
	8	  	 **
	  	 	 	**	 	 
	9	  	 	  	**	 	**	 	 
	10	  	 	  	 	 	 	 	 
	11	  	 TASK 2: Optimization Package prior to Implementation
	  	 	 	 	 	 
	12	  	 **
	  	 	 	**	 	 
	13	  	 	  	**	 	**	 	 
	14	  	 	  	 	 	 	 	 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 69 of 139 / CONFIDENTIAL 

									
	#

	  	 Activities

	  	# of Runs

	 	Price [Euro]

	 	Estimate only

	15	  	 TASK 3 - Implementation
	  	 	 	 	 	 
	16	  	 **
	  	**	 	**	 	 
	17	  	 **
	  	**	 	 	 	 
	18	  	 **
	  	**	 	**	 	 
	19	  	 **
	  	**	 	**	 	Est
	20	  	 	  	 	 	 	 	 
	21	  	 TASK 3A - for Implementation runs
	  	 	 	 	 	 
	22	  	 **
	  	**	 	**	 	Est
	23	  	 **
	  	**	 	 	 	 
	24	  	 **
	  	**	 	 	 	 
	25	  	 **
	  	 	 	**	 	 
	26	  	 **
	  	 	 	 	 	 
	27	  	 **
	  	 	 	 	 	 
	28	  	 	  	**	 	**	 	 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 70 of 139 / CONFIDENTIAL 

									
	 #

	  	 Activities

	  	# of Runs

	 	Price [Euro]

	 	Estimate only

	 29
	  	TASK 4 - Ph II Material (1 GMP batch)	  	 	 	 	 	 
	 30
	  	**	  	**	 	**	 	 
	 31
	  	**	  	 	 	**	 	Est
	 32
	  	**	  	**	 	**	 	 
	 33
	  	**	  	**	 	**	 	 
	 34
	  	**	  	**	 	**	 	 
	 35
	  	**	  	**	 	**	 	 
	 36
	  	**	  	**	 	**	 	 
	 37
	  	**	  	 	 	**	 	 
	 38
	  	 	  	 	 	 	 	 
	 39
	  	TASK 4 A: for Ph II run	  	 	 	 	 	 
	 40
	  	**	  	**	 	**	 	 
	 41
	  	**	  	**	 	 	 	 
	 42
	  	 	  	**	 	**	 	 
	 43
	  	 	  	 	 	 	 	 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 71 of 139 / CONFIDENTIAL 

									
	 #

	  	 Activities

	  	# of Runs

	 	Price [Euro]

	 	Estimate only

	 44
	  	TASK 5 - Ph III Material	  	 	 	 	 	 
	 45
	  	**	  	**	 	**	 	 
	 46
	  	**	  	**	 	**	 	 
	 47
	  	**	  	**	 	**	 	 
	 48
	  	**	  	 	 	**	 	 
	 49
	  	**	  	**	 	**	 	 
	 50
	  	**	  	 	 	**	 	 
	 51
	  	 	  	 	 	 	 	 
	 52
	  	TASK 5 A: for Ph III run	  	 	 	 	 	 
	 53
	  	**	  	**	 	**	 	Est
	 54
	  	**	  	**	 	 	 	 
	 55
	  	 	  	**	 	**	 	 
	 56
	  	 	  	 	 	 	 	 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  
  

 Page 72 of 139 / CONFIDENTIAL 

									
	 #

	  	 Activities

	  	# of Runs

	 	Price [Euro]

	 	Estimate only

	 57
	  	TASK 6 - Validation Batches	  	 	 	 	 	 
	 58
	  	**	  	**	 	**	 	 
	 59
	  	**	  	**	 	 	 	 
	 60
	  	**	  	 	 	**	 	Est
	 61
	  	**	  	 	 	**	 	Est
	 62
	  	**	  	 	 	**	 	 
	 63
	  	 	  	 	 	 	 	 
	 64
	  	TASK 6 A - Validation Batches	  	 	 	 	 	 
	 65
	  	**	  	**	 	**	 	Est
	 66
	  	**	  	**	 	 	 	 
	 67
	  	**	  	**	 	 	 	 
	 68
	  	 	  	**	 	**	 	 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  
  

 Page 73 of 139 / CONFIDENTIAL 

									
	 #

	  	 Activities

	  	# of Runs

	 	Price [Euro]

	 	Estimate only

	 69
	  	TASK 7 - Stability Studies	  	 	 	 	 	 
	 70
	  	Subtask 7A - Cell Banks	  	 	 	 	 	 
	 71
	  	**	  	**	 	**	 	 
	 72
	  	 	  	 	 	 	 	 
	 73
	  	Subtask 7B - Ph II	  	 	 	 	 	 
	 74
	  	**	  	**	 	**	 	 
	 75
	  	**	  	**	 	**	 	 
	 76
	  	**	  	**	 	**	 	 
	 77
	  	**	  	**	 	**	 	 
	 78
	  	 	  	 	 	 	 	 
	 79
	  	Subtask 7C - Ph III	  	 	 	 	 	 
	 80
	  	**	  	**	 	**	 	 
	 81
	  	**	  	**	 	**	 	 
	 82
	  	**	  	**	 	**	 	 
	 83
	  	 	  	 	 	 	 	 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  
  

 Page 74 of 139 / CONFIDENTIAL 

									
	 #

	  	 Activities

	  	# of Runs

	 	Price [Euro]

	 	Estimate only

	 84
	  	Subtask 7D - Conformance Batches	  	 	 	 	 	 
	 85
	  	**	  	**	 	**	 	 
	 86
	  	**	  	**	 	**	 	 
	 87
	  	**	  	**	 	**	 	 
	 88
	  	 	  	**	 	**	 	 
	 89
	  	 	  	 	 	 	 	 
	 	  	 	  	 	 	
	 	 
	 90
	  	TOTAL SUM	  	 	 	11,154,500	 	 
	 	  	 	  	 	 	
	 	 
					
	 **
	  	 	  	 	 	 	 	 
					
	**	  	 	  	 	 	 	 	 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  
  

 Page 75 of 139 / CONFIDENTIAL 

 Exhibit 8: European Countries of the TERRITORY 
  
 Austria 
 Belgium 
 Cyprus 
 Czech Republic 
 Denmark 
 Estonia 
 Finland 
 France 
 Germany 
 Greece 
 Hungary

 Iceland 
 Ireland 
 Italy 
 Latvia 
 Liechtenstein 
 Lithuania 
 Luxembourg 
 Malta 
 Netherlands 
 Norway 
 Poland 
 Portugal 
 Slovakia 
 Slovenia

 Spain 
 Sweden 
 United Kingdom 
  

 Page 76 of 139/ Confidential 

 Exhibit 9: BI Austria patent estate (patent applications) for BI Austria plasmid DNA manufacturing technology

  
 The patent estate listed below covers only such BI Austria patent estate
as relevant for the Corautus DRUG SUBSTANCE and DRUG PRODUCT manufacture. 
  
 Patent Applicant: BI Austria 
  

	1.	Method and devices for producing biomolecules 

  

	2.	Fed-batch fermentation process for the production of plasmid DNA 

  

 Page 77 of 139/ Confidential 

 Exhibit 10: Corautus Patents applicable to DRUG SUBSTANCE and DRUG PRODUCT 
  
 Licensed from Human Genome Sciences, Inc. (HGS) 
  

							
	 Title

	  	 Patent No.
 (App. No.)

	 	 	 Issue Date
 (Filing Date)

	 
	 Vascular Endothelial Growth Factor 2
	  	(08/207,550	)	 	(03/08/1994	)
			
	 Human Vascular Endothelial Growth Factor 2
	  	6,608,182
(08/465,968	 
)	 	08/19/2003
(06/06/1995	 
)
			
	 Polynucleotides Encoding Vascular Endothelial Growth Factor 2
	  	5,935,820
(08/824,996	 
)	 	08/10/1999
(03/27/1997	 
)
			
	 Vascular Endothelial Growth Factor 2
	  	5,932,540
(08/999,811	 
)	 	08/03/1999
(12/24/1997	 
)
			
	 Vascular Endothelial Growth Factor 2
	  	6,040,157
(09/042,105	 
)	 	03/21/2000
(03/13/1998	 
)
			
	 Vascular Endothelial Growth Factor 2
	  	(09/107,997	)	 	(06/30/1998	)

  
 The U.S patents and patent
applications licensed from HGS includes any divisions, reissues, continuations, continuations-in-part, or extensions relating or corresponding to the patents and/or patent applications listed in the table above. The license from HGS also includes
corresponding patents and patent applications from other jurisdictions not listed herein. 
  

 Page 78 of 139/ Confidential 

 Exhibit 11: Project Timelines 
  
 

 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 79 of 139/ Confidential 

 Exhibit 12: Documents provided by Corautus 
  
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 80 of 139/ Confidential 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 81 of 139/ Confidential 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 82 of 139/ Confidential 

 Exhibit 13: Materials provided by Corautus 
  

							
	 Date

	  	 Material Description

	  	Quantity

	  	Received Date

	 August 9, 2004
	  	pVGI.1(VEGF2) Lot # GH00401-3 (as a Reference)	  	50 vials	  	Aug. 14, 2004
	 August 9, 2004
	  	pVGI.1(VEGF2) Lot # GH00401-4	  	80 vials	  	Aug. 14, 2004
	 August 9, 2004
	  	pVGI.1(VEGF2) Working Cell Bank (E. coli), Lot# 36732-2	  	15 vials	  	Aug. 14, 2004
	 October 11, 2004
	  	pVGI.1(VEGF2) Working Cell Bank (E. coli), Lot 36732-2	  	50 vials	  	Oct. 14, 2004
	 March 7, 2005
	  	pVGI.1(VEGF2) Lot # GH00401-3 (as a Reference)	  	150 vials	  	March 9, 2005
	 Pending
	  	VEGF-2 Protein Standard, Lot# GH00404-C11, 3.9 mg/mL	  	TBD	  	N/A
	 Pending
	  	Anti-VEGF-2 poly-antibody	  	TBD	  	N/A
	 Pending
	  	CHO medium	  	TBD	  	As needed
	 Pending
	  	pVGI.1(VEGF2) Master Cell Bank (E. coli), Lot# 36732	  	TBD	  	N/A

 N/A: Will be provided after signing of the
Manufacturing Agreement. 
  

 Page 83 of 139/ Confidential 

 Exhibit 14: Production areas for DRUG SUBSTANCE and DRUG PRODUCT 
  
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 84 of 139/ Confidential 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 85 of 139/ Confidential 

 Exhibit 15: Documentation to be reviewed and approved by Corautus 
  

	•	 	Upstream and Downstream Processing MASTER BATCH RECORDS (Fermentation, Primary Recovery, Chromatographic Steps, Ultra-/Diafiltration and Bulk Filling) for CLINICAL BATCHES and
commercial batches. 

  

	•	 	Sampling plans for CLINICAL BATCHES and commercial batches. 

  

	•	 	Analytical Procedures of transferred analytical methods, supplied by Corautus, or developed specifically for DRUG SUBSTANCE and DRUG PRODUCT by BI Austria. 

 

	•	 	RAW MATERIAL SPECIFICATIONS for RAW MATERIALS as specified in Exhibit 3 of the Quality Agreement. 

  

	•	 	Validation Protocols and Reports for process validation, cleaning validation and validation of transferred assays, as applicable. 

  

	•	 	Stability Protocols and Reports. 

  

	•	 	DRUG SUBSTANCE SPECIFICATIONS. 

  

	•	 	DRUG PRODUCT SPECIFICATIONS. 

  

	•	 	PLACEBO SPECIFICATIONS. 

  

	•	 	Validation master plan. 

  
  

 Page 86 of 139/ Confidential 

 Exhibit 16: Prices for the SERVICES and Payment Schedule 
  
  

 Page 87 of 139/ Confidential 

					
	 Task **

	 	 	 	 
	TASK 0 Feasibility Study	 	 	 	 
	**	 	 	 	 
	 	 	INTERIM SUM #0	 	 
	TASK 1: ** Confirmatory Runs*	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	 	 	INTERIM SUM #1	 	 
	TASK 2: Optimisation Package prior to Implementation	 	 	 	 
	**	 	 	 	 
	 	 	INTERIM SUM #2	 	 
	TASK 3 – Implementation	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	TASK 3A – for Implementation runs	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	 	 	INTERIM SUM #3	 	 
	TASK 4 – Ph II Material (1 GMP batch)	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	TASK 4 A: for Ph II run	 	 	 	 
	**	 	 	 	 
	 	 	INTERIM SUM #4	 	 
	TASK 5 – Ph III Material	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	TASK 5 A: for Ph III run	 	 	 	 
	**	 	 	 	 
	 	 	INTERIM SUM #5	 	 
	TASK 6 – Validation Batches	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	TASK 6 A – Validation Batches	 	 	 	 
	**	 	 	 	 
	 	 	INTERIM SUM #6	 	 
	TASK 7 – Stability Studies	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	**	 	 	 	 
	 	 	INTERIM SUM #7	 	 
	**	 	 	 	 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 88 of 139/ Confidential 

			
	 Task

	 	 
	TASK 0 Feasibility Study	 	 
	**	 	 
	 	 	INTERIM SUM #0
	TASK 1: ** Confirmatory Runs*	 	 
	**	 	 
	**	 	 
	 	 	INTERIM SUM #1
	TASK 2: Optimisation Package prior to Implementation	 	 
	**	 	 
	 	 	INTERIM SUM #2
	TASK 3 – Implementation	 	 
	**	 	 
	**	 	 
	**	 	 
	TASK 3A – for Implementation runs	 	 
	**	 	 
	**	 	 
	**	 	 
	 	 	INTERIM SUM #3
	TASK 4 – Ph II Material (1 GMP batch)	 	 
	**	 	 
	**	 	 
	**	 	 
	**	 	 
	**	 	 
	**	 	 
	TASK 4 A: for Ph II run	 	 
	**	 	 
	 	 	INTERIM SUM #4
	TASK 5 – Ph III Material	 	 
	**	 	 
	**	 	 
	**	 	 
	**	 	 
	TASK 5 A: for Ph III run	 	 
	**	 	 
	 	 	INTERIM SUM #5
	TASK 6 – Validation Batches	 	 
	**	 	 
	**	 	 
	**	 	 
	**	 	 
	TASK 6 A – Validation Batches	 	 
	**	 	 
	 	 	INTERIM SUM #6
	TASK 7 – Stability Studies	 	 
	**	 	 
	**	 	 
	**	 	 
	**	 	 
	 	 	INTERIM SUM #7
	**	 	 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 89 of 139/ Confidential 

							
	 Total Price [EUR]
	 	 **
	  	**	 	**
	 	 	 	  	**	 	**
	 	 	 	  	**	 	**
	 	 	 	  	**	 	**
	 	 	 	  	**	 	**
	 	 	 	  	**	 	**
	 	 	 	  	 	 	

	 	 	 	  	Total [EUR]	 	11.154.500
	 	 	 	  	 	 	

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 90 of 139/ Confidential 

 Exhibit 17: Corautus pre-liminary, non-binding Forecast –in Commercialization 
  
 1. The quantities given below are “gram of DRUG
SUBSTANCE”. 
  

										
	 Territory

	  	2007

	  	2008

	  	2009

	  	2010

	 
	 US
	  	0	  	0	  	0	  	*	*

  
 2.
The quantities given below are “number of DRUG PRODUCT vials”. 
  

												
	 Territory

	  	Concentration

	 	2007

	  	2008

	  	2009

	  	2010

	 
	 US
	  	133.3ug/mL*	 	0	  	0	  	0	  	*	*
	 US
	  	OR
33.3ug/mL*	 	0	  	0	  	0	  	*	*

  
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 91 of 139/ Confidential 

 Exhibit 18: Rolling Forecast Model 
  
 The Rolling Forecast Model has three different zones. Each zone is divided into calendar quarters. The first zone, containing the first four
(4) quarters (Red Zone), are firm orders which can not be changed. The second zone, containing quarters 5 to 8 (Blue Zone), are a binding forecast where only one change for a given quarter is permitted. To make a change for a quarter in the Blue
Zone, Corautus shall advise BI Austria in writing of the change. Changes which increase the forecast by **% or less do not require consent of BI Austria. If Corautus reduces the binding forecast for the Blue Zone by more than ** percent, then
Corautus shall be obligated to pay for DRUG PRODUCT which was not ordered in excess of the ** percent reduction at the rate of ** percent of the unit price of the DRUG PRODUCT then in effect. Such payment will not be due prior to the quarter for
which there has been a reduction of an amount in excess of ** percent and will not be due if and to the extent such reduction in a quarter is later on reversed by a higher forecast for the same quarter. The quarters 9 through 12 (Green Zone) are for
information only and are not binding. 
  
 At least ** months prior to Corautus
requested first delivery of DRUG PRODUCT in PERIOD THREE Corautus shall send a forecast for the ** calendar quarters of production (which forecast may commence on the first day of any calendar quarter). After the first forecast is given Corautus
will update the forecast on a quarterly basis at the latest on the first day of each ensuing calendar quarter during the term of this AGREEMENT. 
  
 The forecast given by Corautus shall become binding no later than ** months prior to Corautus requested first delivery of DRUG PRODUCT in PERIOD THREE and all orders by
Corautus shall be subject to the Rolling Forecast Model. 
  
 The rolling forecast
is for vials of DRUG PRODUCT. 
  
 Corautus has submitted a non-binding rolling
forecast under Section 10.2.2 of the AGREEMENT as shown on Exhibit 17 which has no effect. The table below is an example of the Rolling Forecast Model (these numbers do not reflect the actual quantity of DRUG PRODUCT to be manufactured in accordance
with this AGREEMENT and serve for explanatory purposes only). 
  

 Page 92 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 93 of 139/ Confidential 

			
	 	  	= firm order
	 	  	= binding forecast (** % change allowed only
once)
	 	  	= forecast only for information
	no cha.	  	= no further change allowed

  
 Remarks: 
  
 Number of vials DRUG PRODUCT; numbers in thousands

 Quarters in light color mean non-binding forecasts (“pre-notice period”) ending ** months prior to the first requested delivery date of DRUG
PRODUCT. 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 94 of 139/ Confidential 

 Exhibit 19: Documents to be provided by BI Austria in English 
  
 Specific documents shall be either drafted in English or translated into English,
respectively (this applies to all production scales): 
  

	 	•	 	Translation: Upstream and Downstream Processing MASTER BATCH RECORDS (Fermentation, Primary Recovery, Chromatographic Steps, Ultra-/Diafiltration and Bulk Filling) for the
first CLINICAL BATCH. 

  
 The changes made to the
implementation batches shall be summarized (in English) and provided with the revised Upstream and Downstream Processing MASTER BATCH RECORDS for the first CLINICAL BATCH. 
  

	 	•	 	Translation: Revised Upstream and Downstream Processing MASTER BATCH RECORDS (Fermentation, Primary Recovery, Chromatographic Steps, Ultra-/Diafiltration and Bulk Filling)
for the first commercial batch (all further revisions shall not be translated by BI Austria). 

  

	 	•	 	Translation: Sampling Plans for MASTER BATCH RECORDS for the first CLINICAL BATCH and for revised MASTER BATCH RECORDS for the first commercial batch.

  

	 	•	 	Translation: All product-related Procedures of Analytical Methods, referenced in their corresponding Method Validation Protocols for Clinical Phase III.

  

	 	•	 	Translation: RAW MATERIAL SPECIFICATIONS for RAW MATERIALS as specified in Exhibit 3 of the Quality Agreement. 

  

	 	•	 	Validation Protocols and Reports for process validation, cleaning validation and validation of transferred analytical methods (either in English or translated into English), as
applicable. 

  

	 	•	 	Product-specific Technical Protocols and/or Reports for collection of data, transfer of validated methods or about development work. 

  

	 	•	 	Stability Protocols and Reports. 

  

	 	•	 	DRUG PRODUCT SPECIFICATIONS. 

  

	 	•	 	DURG SUBSTANCE SPECIFICATIONS. 

  

	 	•	 	Comments included in the filled-in German BATCH RECORDS during the manufacture for the batches as defined for the “Qualification Period” in the QUALITY AGREEMENT.

  

	 	•	 	PLACEBO SPECIFICATION. 

  

 Page 95 of 139/ Confidential 

	 	•	 	Validation master plan. 

  

	 	•	 	COA. 

  

	 	•	 	COC. 

  

	 	•	 	This Quality Agreement. 

  

	 	•	 	Deviation summary reports. 

  

 Page 96 of 139/ Confidential 

 Exhibit 20: Mutually agreed Production Requirements 
  
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 97 of 139/ Confidential 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 98 of 139/ Confidential 

 Exhibit 21: Project Team 
  

Corautus 
  

					
	 Surname

	 	First Name

	 	 Position

	**	 	**	 	Chief Scientific Officer
	**	 	**	 	Quality Control &Assay Development
	**	 	**	 	Project Manager
	**	 	**	 	Pre-clinical Study & Manufacturing Operation
	**	 	**	 	Quality Assurance

  
 BI Austria 
  

					
	Surname

	 	First Name

	 	 Position

	**	 	**	 	Quality Management
	**	 	**	 	Production, F&F
	**	 	**	 	Project Manager
	**	 	**	 	Production, Fermentation
	**	 	**	 	Production, Purification
	**	 	**	 	Quality Control
	**	 	**	 	Process Science

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 99 of 139/ Confidential 

 Exhibit 22: Steering Committee 
  
 Corautus Genetics 
  

					
	Surname

	 	Name

	 	 Position

	**	 	**	 	Project Manager
	**	 	**	 	Sr. VP and Chief Scientific Officer
	**	 	**	 	Director, Preclinical Studies and Manufacturing Operation
	**	 	**	 	VP, Finance

  
 BI Austria 
  

					
	Surname

	 	Name

	 	 Position

	**	 	**	 	Project Manager
	**	 	**	 	Head, Customer Relations & Projects
	**	 	**	 	Head, Planning and Co-ordination
	**	 	**	 	Head, Biopharmaceuticals/Operation

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 100 of 139/ Confidential 

 Exhibit 23: Termination Fee 
  
 Model calculation based on the scope of SERVICES as of the Effective Date of the AGREEMENT (price basis 2005). 
 All figures in Euro. 
  
 (A) Termination Fee due under Section 27.2.1 of the AGREEMENT 
  
 Case 1: Task 6 and 6(a) not included 
  
 The PARTIES acknowledge that any payments due for Task 7 are not included in this model calculation. 
  
 1. Termination Notice in PERIOD 1 (Task 3) 
  

									
	 Payments due

	  	Payments for Services

	 	 Payments due unless
 already paid

	  	Termination Fee

	 PERIOD 1
	  	** % Task 0	  	**	 	ü	  	 
	 	  	** % Task 1	  	**	 	ü	  	 
	 	  	** % Task 2	  	**	 	ü	  	 
	 	  	** % Task 3	  	 	 	 	  	**
					
	 PERIOD 2
	  	** % Task 4	  	 	 	 	  	**
	 	  	 	  	 	 	 	  	

	 	  	 	  	Total Termination Fee due	  	2,870,650
	 	  	 	  	 	 	 	  	

	
	2. Termination Notice in PERIOD 2 (Task 4)
				
	 Payments due

	  	Payments for Services

	 	Payment made upon
Termination

	  	Termination Fee

	 PERIOD 1
	  	** % PERIOD 1	  	**	 	ü	  	 
					
	 PERIOD 2
	  	** % Task 4	  	 	 	 	  	**
	 	  	** % Task 5	  	 	 	 	  	**
	 	  	 	  	 	 	 	  	

	 	  	 	  	Total Termination Fee due	  	2,065,750
	 	  	 	  	 	 	 	  	

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 101 of 139/ Confidential 

 3. Termination Notice in PERIOD 2 (Task 5) 
  

									
	 Payments due

	  	Payments for Services

	 	Payments due unless already
paid

	  	Termination Fee

	 PERIOD 1
	  	**% PERIOD 1	  	**	 	ü	  	 
					
	 PERIOD 2
	  	** % Task 4	  	**	 	ü	  	 
	 	  	** % Task 5	  	 	 	 	  	**
	 	  	 	  	 	 	 	  	

	 	  	 	  	Total Termination Fee due	  	1,140,900
	 	  	 	  	 	 	 	  	

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 102 of 139/ Confidential 

 (A) Termination Fee due under Section 27.2.1 of the AGREEMENT 
  
 Case 2: Task 6 and 6(a) included 
  
 The PARTIES acknowledge that any payments due for Task 7 are not included in this model
calculation. 
  
 1. Termination Notice in PERIOD 1 (Task 3) 
  

									
	 Payments due

	  	Payments for Services

	 	Payments due unless already paid

	  	Termination Fee

	 PERIOD 1
	  	** % Task 0	  	**	 	ü	  	 
	 	  	** % Task 1	  	**	 	ü	  	 
	 	  	** % Task 2	  	**	 	ü	  	 
	 	  	** % Task 3	  	 	 	 	  	**
					
	 PERIOD 2
	  	** % Task 4	  	 	 	 	  	**
	 	  	 	  	 	 	 	  	

	 	  	 	  	Total Termination Fee due	  	2,870,650
	 	  	 	  	 	 	 	  	

  
 2. Termination Notice in PERIOD 2
(Task 4) 
  

									
				
	 Payments due

	  	Payments for Services

	 	Payments due unless already paid

	  	Termination Fee

	 PERIOD 1
	  	**% PERIOD 1	  	**	 	ü	  	 
					
	 PERIOD 2
	  	** % Task 4	  	 	 	 	  	**
	 	  	** % Task 5	  	 	 	 	  	**
	 	  	 	  	 	 	 	  	

	 	  	 	  	Total Termination Fee due	  	2,065,750
	 	  	 	  	 	 	 	  	

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

	

  

 Page 103 of 139/ Confidential 

 3. Termination Notice in PERIOD 2 (Task 5) 
  

										
	 Payments due

	  	Payments for Services

	 	 Payments due unless
 already paid

	  	Termination Fee

	 
	 PERIOD 1
	  	**% PERIOD 1	  	**	 	ü	  	 	 
					
	 PERIOD 2
	  	** % Task 4	  	**	 	ü	  	 	 
	 	  	** % Task 5	  	 	 	 	  	*	*
	 	  	** % Task 6	  	 	 	 	  	*	*
	 	  	 	  	 	 	 	  	
	

	 	  	 	  	Total Termination Fee due	  	3,068,450	 
	 	  	 	  	 	 	 	  	
	

  
 4. Termination Notice in PERIOD 2

  

													
	 (Task 6) Payments due

	  	Payments for Services

	 	 Payments due unless
 already paid

	    	Termination Fee if
firm order was
placed by Corautus

	 	 	Termination Fee if no firm
order was placed by
Corautus

	 
	 PERIOD 1
	  	**% PERIOD 1	  	**	 	ü	    	 	 	 	 	 
						
	 PERIOD 2
	  	** % Task 4 + 5	  	**	 	ü	    	 	 	 	 	 
						
	 PERIOD 2
	  	** % Task 6	  	 	 	 	    	 	 	 	 	 
	 	  	Assumption 50 % work done	  	**	 	ü	    	 	 	 	 	 
	 	  	Assumption 50 % work scheduled	  	 	 	 	    	*	*	 	*	*
						
	 PERIOD 3
	  	** % of DP in Red Zone (a)	  	 	 	 	    	*	*	 	 	 
	 	  	 	  	 	 	 	    	
	
	 	
	

	 	  	 	  	Total Termination Fee due	    	2,731,650	 	 	1,927,550	 
	 	  	 	  	 	 	 	    	
	
	 	
	

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 104 of 139/ Confidential 

 (B) Termination Fee due under Section 27.3.2 of the AGREEMENT 
  
 Case 1: Task 6 and 6(a) not included 
  
 1. Example: Termination Notice in Dec 2005 
  

											
	 	  	Payments for Services

	 	 Payments due unless
 already paid

	  	Termination Fee

	 	Period

	 PERIOD 1
	  	**% PERIOD 1	  	**	 	ü	  	 	 	 
	 PERIOD 2
	  	**% Task 4	  	**	 	ü	  	 	 	 
	 	  	**% for work done in Task 5	  	**	 	ü	  	 	 	 
	 	  	** % of scheduled work Task 5	  	 	 	 	  	**	 	Remaining work in
2006
	 Task 7 (Stability)
	  	** % of payments for 2005 and Jan - Jun 2006	  	**	 	ü	  	**	 	Jan - Jun 2006
	 	  	 	  	 	 	 	  	
	 	 
	 	  	 	  	Total Termination Fee due	  	595,100	 	 
	 	  	 	  	 	 	 	  	
	 	 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 105 of 139/ Confidential 

 2. Example: Termination Notice in Dec 2006 
  

											
	 	  	 Payments for Services

	  	 Payments due unless
 already paid

	  	Termination Fee

	  	 Period

						
	 PERIOD 1
	 	 **% PERIOD 1
	  	**	  	ü	  	 	  	 
						
	 PERIOD 2
	 	 **% PERIOD 2 (excl. Tasks 6 + 6(a)
	  	**	  	ü	  	 	  	 
	 	 	 	  	 	  	n	  	 	  	 
						
	 Task 7 (Stability)
	 	 **% of payments for 2005, 2006 and Jan - Jun 2007
	  	**	  	ü	  	221,785	  	Jan - Jun 2007
	 	 	 	  	 	  	 	  	
	  	 
	 	 	 	  	 	  	Total Termination Fee due	  	221,785	  	 
	 	 	 	  	 	  	 	  	
	  	 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 106 of 139/ Confidential 

 (B) Termination Fee due under Section 27.3.2 of the AGREEMENT 
  
 Case 2: Task 6 and 6(a) included 
  
 1. Example: Termination Notice in Dec 2005 
  

												
	 	  	 Payments for Services

	  	 Payments due unless
 already paid

	  	Termination Fee

	 	 	 Period

	 PERIOD 1
	  	**% PERIOD 1	  	**	  	ü	  	 	 	 	 
						
	 PERIOD 2
	  	**% Task 4	  	**	  	ü	  	 	 	 	 
	 	  	 **% for work done in
 Task 5
	  	**	  	ü	  	 	 	 	 
	 	  	 **% of scheduled work
 Task 5
	  	 	  	 	  	*	*	 	Remaining work in 2006
	 	  	**% Task 6	  	 	  	 	  	*	*	 	12 Months = 2006
						
	 Task 7 (Stability)
	  	 **% of payments for
 2005
 and Jan -Jun 2006
	  	**	  	ü	  	*	*	 	Jan - Jun 2006
	 	  	 	  	 	  	 	  	
	
	 	 
	 	  	 	  	 	  	Total Termination Fee due	  	3,981,935	 	 	 
	 	  	 	  	 	  	 	  	
	
	 	 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 107 of 139/ Confidential 

 2. Example: Termination Notice in Dec 2006 
  

											
	 	  	 Payments for
Services

	  	 Payments due unless
 already paid

	  	 Termination Fee

	  	 Period

	 PERIOD 1
	  	**% PERIOD 1	  	**	  	ü	  	 	  	 
						
	 PERIOD 2
	  	** % PERIOD 2	  	**	  	ü	  	 	  	 
	 	  	** % Task 6	  	 	  	n	  	**	  	12 Months = 2007
						
	 Task 7 (Stability)
	  	** % of payments for 2005, 2006 and Jan - Jun 2007	  	**	  	ü	  	**	  	Jan - Jun 2007
	 	  	 	  	 	  	 	  	
	  	 
	 	  	 	  	 	  	Total Termination Fee due	  	3,498,620	  	 
	 	  	 	  	 	  	 	  	
	  	 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 108 of 139/ Confidential 

 Exhibit 24: Price formula for DRUG SUBSTANCE and DRUG PRODUCT manufactured in PERIOD THREE 
  
 (a) DRUG SUBSTANCE 
  
 Irrespective of the amount of DRUG PRODUCT ordered by Corautus, Corautus shall be obligated to pay the entire price of all batches of DRUG
SUBSTANCE necessary to produce the requested quantity of DRUG PRODUCT. The price for one batch DRUG SUBSTANCE ** shall be ** Euro (price basis 2005). The entire batch price of ** Euro is due upon release of the biomass. 
  
 (b) DRUG PRODUCT 
  
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 109 of 139/ Confidential 

 (b) DRUG PRODUCT 
  
 Price basis: 2005 
  
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 110 of 139/ Confidential 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 111 of 139/ Confidential 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  
  

 Page 112 of 139/ Confidential 

 Exhibit 25: Quality Agreement 
  
 Quality Agreement 
 between 
  

			
	Boehringer Ingelheim Austria GmbH	 	(hereinafter BI Austria)
	Dr. Boehringer-Gasse 5-11,	 	 
	A-1121 Vienna, Austria	 	 

  
 and 

 

			
	Corautus Genetics, Inc.	 	(hereinafter Corautus)
	75 Fifth Street, NW, Suite 313	 	 
	30308 Atlanta, GA	 	 
	U.S.A.	 	 

  
  

 Page 113 of 139/ Confidential 

 Table of Contents: 
  

			
	1.	  	Scope
		
	2.	  	Definitions
		
	3.	  	Quality Contacts
		
	4.	  	General Statement on Tasks and Responsibilities
		
	5.	  	Specific Quality Related Responsibilities
		
	6.	  	DRUG PRODUCT-specific Master Documents and Quality Records
		
	7.	  	Quality Control Testing and Issuance of Certificates
		
	8.	  	MANUFACTURER’S RELEASE and FINAL RELEASE
		
	9.	  	Reserve Samples
		
	10.	  	Stability Testing
		
	11.	  	Storage and Shipment of DRUG PRODUCT
		
	12.	  	Deviations, OOS
		
	13.	  	Validations
		
	14.	  	Change Control
		
	15.	  	Regulatory Submissions
		
	16.	  	Audits and Compliance
		
	17.	  	Inspections by HEALTH AUTHORITIES
		
	18.	  	Complaints, DRUG PRODUCT Recalls and Biological Deviations
		
	19.	  	Annual Product Review
		
	20.	  	Confidentiality
		
	21.	  	Termination and Survival
		
	22.	  	References to “Days”
		
	23.	  	Dispute Resolution
		
	24.	  	Amendments
		
	25.	  	Effective Date / Signature Page
	
	List of Exhibits

  
  

 Page 114 of 139/ Confidential 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 115 of 139/ Confidential 

 Exhibit 26: Stability Studies 
  
 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 116 of 139/ Confidential 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 117 of 139/ Confidential 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 118 of 139/ Confidential 

 ** 

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 119 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 120 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 121 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 122 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 123 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 124 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 125 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 126 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 127 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 128 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 129 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 130 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 131 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 132 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  
  

 Page 133 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  
  

 Page 134 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  
  

 Page 135 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  
  

 Page 136 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 137 of 139/ Confidential 

 ** 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 138 of 139/ Confidential 

 Exhibit 27: Sterility DRUG SUBSTANCE 
  
 The DRUG SUBSTANCE would be sterile filtered into suitable containers; the currently specified DRUG SUBSTANCE container is a polypropylene
bottle; filling volume ** DRUG SUBSTANCE. A total of approx. ** would be filled from one DRUG SUBSTANCE batch. 
  
 ** 
  
 The price for the respective work is **.

  
 In accordance with the USP 10 % or 4 containers, whichever is greater, must be
tested for sterility if there are not more than 100 containers. 
  

	**	Confidential provision omitted and filed separately with the Securities and Exchange Commission (“SEC”), based upon a request for confidential treatment filed with the
SEC. 

  

 Page 139 of 139/ Confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}]]